EP2178558B1

Yersinia pestis antigens, vaccine compositions, and related methods

Abstract

This record has no abstract on file.

EP2178558B1, drawing sheet 1 — Sheet 1 of 45

Term

1.8 yearsleft in the term

Expires 11 July 2028.

10 claims: 2 independent, 8 dependent

1
An antigen comprising a Yersinia pestis protein fused to a thermostable protein; wherein the antigen comprises an amino acid sequence that is about 90% identical, about 91 % identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO:27.
4
The antigen of any one of claims 1 to 3, wherein said antigen is capable of eliciting an immune response against Yersinia pestis.
5
A composition comprising an antigen according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier;wherein the composition is capable of eliciting an immune response upon administration to a subject.
6
An antigen according to any one of claims 1 to 4 for use in inducing a protective immune response against Yersinia pestis infection in a subject.
7
A method for producing an antigen according to any one of claims 1 to 4, the method comprising:providing a nucleic acid construct encoding an antigen according to any one of claims 1 to 4;introducing the nucleic acid construct into a cell;and incubating the cell under conditions favorable for expression of the antigen protein, thereby producing the antigen.
10
An isolated nucleic acid construct comprising nucleic acid sequence encoding an antigen according to any one of claims 1 to 4.

Independent claims6

333 paragraphs, as filed

Cross-Reference to Related Applications

0001This application claims priority under 35 U.S.C. § 119(e) to United States provisional patent application, <patcit id="pcit0001" dnum="USSN60949115A"><text>U.S.S.N. 60/949,115, filed July 11, 2007</text></patcit> ("the '115 application").

Background of the Invention

0002Historically plague has been a major infectious disease afflicting human populations, leading to millions of deaths. The etiologic agent of plague is Yersinia pestis and infection with this pathogen can develop into a highly contagious pneumonic disease with almost 100% lethality. Continued outbreaks of plague, along with the suitability of Y. pestis for weaponization has heightened interest in developing a vaccine. Currently, there is no safe and effective vaccine against Y. pestis.

0003Thus, there is a need to provide sources of vaccines and antigens for production of vaccines. Improved vaccine design and development, as well as methods of making and using such compositions of matter are needed which provide inexpensive and highly accessible sources of such therapeutic and/or prophylactic compositions.

Summary of the Invention

0004The present invention provides Yersinia pestis antigens and vaccine components produced in plants as defined in the appended claims. The present invention provides a Y. pestis antigen generated as a fusion with a thermostable protein (e.g. lichenase). The invention provides vaccine compositions containing said Y. pestis antigen. The Y. pestis vaccine comprises two different Y. pestis antigens. Still further provided are methods for production and use of antigen and vaccine compositions in accordance with the invention.

Brief Description of the Drawing

0005<figref idref="f0001 f0002 f0003 f0004 f0005 f0006 f0007 f0008 f0009 f0010 f0011 f0012 f0013 f0014 f0015 f0016 f0017 f0018 f0019 f0020 f0021 f0022 f0023 f0024">Figures 1a - 1x</figref>. Alignment of amino acid sequences of Lcr V protein from multiple Y. pestis strains. CLUSTAL W multiple sequence alignments of LcrV amino acid sequences from 64 different Y. pestis strains (GenBank accession numbers NP_863514.1; NP_783665.1; NP_052392.1; AAK69213.1; AAN37531.1; AAD16815.1; YP_068466.1; CAF25400.1; P0C556.1; NP_995380.1; AAS58571.1; ZP_02318603.1; ZP_02314654.1; ZP_02314147.1; ZP_02314145.1; ZP_02307430.1; EDR63976.1; EDR60080.1; EDR55652.1; EDR55650.1; EDR55212.1; ZP_02240571.1; EDR48750.1;EDR41684.1; ZP_02232674.1; ZP_02228629.1; ZP_02223652.1; EDR37557.1; EDR30648.1; YP_001604463.1; ABX88711.1; CAB54908.1; ABF48194.1; ABF48193.1; ABF48192.1; ABF48191.1; ABF48190.1; ABF48189.1; NP_395165.1; YP_001293940.1; NP_857946.1; NP_857751.1; ABR68791.1; ABR68790.1; ABR68789.1; ABR68788.1; ABR14856.1; AAC69799.1; AAC62574.1; AAF64077.1; A4TSQ1.1; YP_001004069.1; CAL10039.1; P23994.1; AAA27645.1; AAF64076.1; YP_636823.1; ABG16274.1; ABP42325.1; YP_001154615.1; ABB16313.1; YP_001874676.1; ACC91219.1; ABI97154.1) aligned with the sequence of LcrV that was used in the production of antigen constructs in the Exemplification ("LcrV.pro").

0006<figref idref="f0025">Figure 2</figref>. In vitro characterization of plant produced Y. pestis antigens. Plant-produced LicKM (Lane 1), LicKM-LcrV (Lane 2), and LicKM-F1 (Lane 3) were analyzed by SDS-PAGE followed by Coomassie staining (A) and immunoblotting using rabbit polyclonal anti-LicKM (B), mouse monoclonal anti-LcrV (C), and mouse monoclonal anti-F 1 (D) antibodies.

0007<figref idref="f0026">Figure 3</figref>. Antibody responses elicited by plant-produced plague vaccine antigens and their protective efficacy against Y. pestis challenge. Serum samples were tested by ELISA for the presence of LcrV- (A and C) and F1- (B and D) specific IgG (A and C) and IgA (B and D). Data are represented as average titer ± standard deviation. Animals were challenged with 100 × LD50 aerosolized Y. pestis, and the percent survivors for each experimental group were graphed over time (E).

0008<figref idref="f0027">Figure 4</figref>. Production of LcrV-FI-LicKM fusion protein. Lanes 1 - 4: Coomassie Brilliant Blue staining. Lanes 5 - 8: western blot using α-lichenase antibody. Lanes 1 and 5: molecular weight markers. Lane 2: bovine serum albumin. Lanes 3 and 7: LcrV-LicKM fusion. Lanes 4 and 8: LcrV-F1-LicKM fusion protein, wherein LcrV is inserted into the loop region of LicKM, and F 1 is fused to LicKM as a C-terminal fusion. Lane 6: LicKM-LF fusion.

0009<figref idref="f0028">Figure 5</figref>. Antibody responses elicited by plant-produced plague vaccine antigens and their protective efficacy against Y. pestis challenge. Serum samples were tested by ELISA for the presence of LcrV- (A and C) and F1- (B and D) specific IgG. Data are represented as average titer ± standard deviation. The graphs shown in (A) and (B) differ from those in (C) and (D) only in the scale of the Y-axis.

0010<figref idref="f0029">Figure 6</figref>. Survival of groups of female cynomolgus monkeys vaccinated three times subcutaneously or subcutaneously as a priming vaccination followed by twice intranasal vaccinations. The two plant-produced antigens (i.e., F1 and LcrV) were presented to monkeys as a mixture of independently-derived fusion products with LicKM or as a double fusion product (LicKM-F1-LcrV). Group 1 (••••••), a control group with LicKM, received 125 µg LicKM plus two adjuvants. Group 2 (— — —) monkeys received 250 µg LicKM-F1 and LicKM-LcrV mixture plus two adjuvants. Both groups were vaccinated subcutaneously, thrice. Group 3 (-••-••-••), a control group, received 125 µg LicKM plus two adjuvants as a subcutaneous priming dose followed by two intranasal doses without adjuvant at two week intervals. Group 4 (- - - -) received 250 µg LicKM-F1 and LicKM-LcrV mixture plus two adjuvants as a subcutaneous priming dose followed by two intranasal doses without adjuvant at two week intervals. Group 5 (————) received 250 µg LicKM-F1-LcrV double fusion product plus two antigens three times subcutaneously at two week intervals. On post-infection day 0 (Study Day 40), all monkeys were exposed to multiple LD50 inhalation dose of Y. pestis CO92. Monkeys were followed up to post-infection day 14 (Study Day 54).

Definitions

0011Amino acid: As used herein, term "amino acid," in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain. In some embodiments, an amino acid has the general structure H2N-C(H)(R)-COOH. In some embodiments, an amino acid is a naturally-occurring amino acid. In some embodiments, an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. "Standard amino acid" refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. "Nonstandard amino acid" refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. As used herein, "synthetic amino acid" encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and/or substitutions. Amino acids, including carboxy- and/or amino-terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, and/or substitution with other chemical groups that can change the peptide's circulating half-life without adversely affecting their activity. Amino acids may participate in a disulfide bond. The term "amino acid" is used interchangeably with "amino acid residue," and may refer to a free amino acid and/or to an amino acid residue of a peptide. It will be apparent from the context in which the term is used whether it refers to a free amino acid or a residue of a peptide.

0012Animal: As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to humans, at any stage of development. In some embodiments, "animal" refers to non-human animals, at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically-engineered animal, and/or a clone.

0013Antibody: As used herein, the term "antibody" refers to any immunoglobulin, whether natural or wholly or partially synthetically produced. All derivatives thereof which maintain specific binding ability are also included in the term. The term also covers any protein having a binding domain which is homologous or largely homologous to an immunoglobulin binding domain. Such proteins may be derived from natural sources, or partly or wholly synthetically produced. An antibody may be monoclonal or polyclonal. An antibody may be a member of any immunoglobulin class, including any of the human classes: IgG, IgM, IgA, IgD, and IgE. As used herein, the terms "antibody fragment" or "characteristic portion of an antibody" are used interchangeably and refer to any derivative of an antibody which is less than full-length. In general, an antibody fragment retains at least a significant portion of the full-length antibody's, specific binding ability. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, scFv, Fv, dsFv diabody, and Fd fragments. An antibody fragment may be produced by any means. For example, an antibody fragment may be enzymatically or chemically produced by fragmentation of an intact antibody and/or it may be recombinantly produced from a gene encoding the partial antibody sequence. Alternatively or additionally, an antibody fragment may be wholly or partially synthetically produced. An antibody fragment may optionally comprise a single chain antibody fragment. Alternatively or additionally, an antibody fragment may comprise multiple chains which are linked together, for example, by disulfide linkages. An antibody fragment may optionally comprise a multimolecular complex. A functional antibody fragment typically comprises at least about 50 amino acids and more typically comprises at least about 200 amino acids.

0014Approximately: As used herein, the term "approximately" or "about," as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term "approximately" or "about" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

0015Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, and/or 3' end formation); (3) translation of an RNA into a polypeptide or protein; (4) post-translational modification of a polypeptide or protein.

0016Gene: As used herein, the term "gene" has its meaning as understood in the art. It will be appreciated by those of ordinary skill in the art that the term "gene" may include gene regulatory sequences (e.g., promoters, enhancers, etc.) and/or intron sequences. It will further be appreciated that definitions of gene include references to nucleic acids that do not encode proteins but rather encode functional RNA molecules such as tRNAs. For the purpose of clarity we note that, as used in the present application, the term "gene" generally refers to a portion of a nucleic acid that encodes a protein; the term may optionally encompass regulatory sequences, as will be clear from context to those of ordinary skill in the art. This definition is not intended to exclude application of the term "gene" to non-protein-coding expression units but rather to clarify that, in most cases, the term as used in this document refers to a protein-coding nucleic acid.

0017Gene product: As used herein, the term "gene product" or "expression product" generally refers to an RNA transcribed from the gene (pre-and/or post-processing) or a polypeptide (pre- and/or post-modification) encoded by an RNA transcribed from the gene.

0018Homology: As used herein, the term "homology" refers to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% identical. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% similar.

0019Identity: As used herein, the term "identity" refers to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or about 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of <nplcit id="ncit0001" npl-type="s"><text>Meyers and Miller (CABIOS, 1989, 4: 11-17</text></nplcit>), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

0020Isolated: As used herein, the term "isolated" refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, about 99%, substantially 100%, or 100% of the other components with which they were initially associated. In some embodiments, isolated agents are more than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, substantially 100%, or 100% pure. As used herein, a substance is "pure" if it is substantially free of other components. As used herein, the term "isolated cell" refers to a cell not contained in a multi-cellular organism.

0021Nucleic acid: As used herein, the term "nucleic acid," in its broadest sense, refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. In some embodiments, "nucleic acid" refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides). In some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising individual nucleic acid residues. As used herein, the terms "oligonucleotide" and "polynucleotide" can be used interchangeably. In some embodiments, "nucleic acid" encompasses RNA as well as single and/or double-stranded DNA and/or cDNA. Furthermore, the terms "nucleic acid," "DNA," "RNA," and/or similar terms include nucleic acid analogs, i.e. analogs having other than a phosphodiester backbone. For example, the so-called "peptide nucleic acids," which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention. The term "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and/or encode the same amino acid sequence. Nucleotide sequences that encode proteins and/or RNA may include introns. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, backbone modifications, etc. A nucleic acid sequence is presented in the 5' to 3' direction unless otherwise indicated. The term "nucleic acid segment" is used herein to refer to a nucleic acid sequence that is a portion of a longer nucleic acid sequence. In many embodiments, a nucleic acid segment comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more residues. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5'-N-phosphoramidite linkages). In some embodiments, the present invention may be specifically directed to "unmodified nucleic acids," meaning nucleic acids (e.g. polynucleotides and residues, including nucleotides and/or nucleosides) that have not been chemically modified in order to facilitate or achieve delivery.

0022Operably linked: As used herein, the term "operably linked" refers to a relationship between two nucleic acid sequences wherein the expression of one of the nucleic acid sequences is controlled by, regulated by, modulated by, etc., the other nucleic acid sequence. For example, the transcription of a nucleic acid sequence is directed by an operably linked promoter sequence; post-transcriptional processing of a nucleic acid is directed by an operably linked processing sequence; the translation of a nucleic acid sequence is directed by an operably linked translational regulatory sequence; the transport or localization of a nucleic acid or polypeptide is directed by an operably linked transport or localization sequence; and the post-translational processing of a polypeptide is directed by an operably linked processing sequence. A nucleic acid sequence that is operably linked to a second nucleic acid sequence may be covalently linked, either directly or indirectly, to such a sequence, although any effective three-dimensional association is acceptable.

0023Portion: As used herein, the phrase a "portion" or "fragment" of a substance, in the broadest sense, is one that shares some degree of sequence and/or structural identity and/or at least one functional characteristic with the relevant intact substance. For example, a "portion" of a protein or polypeptide is one that contains a continuous stretch of amino acids, or a collection of continuous stretches of amino acids, that together are characteristic of a protein or polypeptide. In some embodiments, each such continuous stretch generally will contain at least about 2, about 5, about 10, about 15, about 20 or more amino acids. In general, a portion is one that, in addition to the sequence identity specified above, shares at least one functional characteristic with the relevant intact protein. In some embodiments, the portion may be biologically active.

0024Protein: As used herein, the term "protein" refers to a polypeptide (i.e., a string of at least two amino acids linked to one another by peptide bonds). Proteins may include moieties other than amino acids (e.g., may be glycoproteins, proteoglycans, etc.) and/or may be otherwise processed or modified. Those of ordinary skill in the art will appreciate that a "protein" can be a complete polypeptide chain as produced by a cell (with or without a signal sequence), or can be a characteristic portion thereof. Those of ordinary skill will appreciate that a protein can sometimes include more than one polypeptide chain, for example linked by one or more disulfide bonds or associated by other means. Polypeptides may contain L-amino acids, D-amino acids, or both and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, e.g., terminal acetylation, amidation, etc. In some embodiments, proteins may comprise natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof. The term "peptide" is generally used to refer to a polypeptide having a length of less than about 100 amino acids.

0025Similarity: As used herein, the term "similarity" refers to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of percent similarity of polymeric molecules to one another can be performed in the same manner as a calculation of percent identity, except that calculation of percent similarity takes into account conservative substitutions as is understood in the art.

0026Subject: As used herein, the term "subject" or "patient" refers to any organism to which compositions in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; etc.).

0027Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term "substantially" is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

0028Suffering from: An individual who is "suffering from" a disease, disorder, and/or condition has been diagnosed with or displays one or more symptoms of the disease, disorder, and/or condition.

0029Susceptible to: An individual who is "susceptible to" a disease, disorder, and/or condition has not been diagnosed with the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may not exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.

0030Therapeutically effective amount: As used herein, the term "therapeutically effective amount" of a therapeutic agent means an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the symptom(s) of the disease, disorder, and/or condition.

0031Therapeutic agent: As used herein, the phrase "therapeutic agent" refers to any agent that, when administered to a subject, has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect.

0032Treatment: As used herein, the term "treatment" (also "treat" or "treating") refers to any administration of a biologically active agent that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, prevents, reduces severity of and/or reduces incidence of one or more symptoms or features of a particular disease, disorder, and/or condition. Such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition. Alternatively or additionally, such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition.

0033Vectors: As used herein, "vector" refers to a nucleic acid molecule which can transport another nucleic acid to which it has been linked. In some embodiment, vectors can achieve extra-chromosomal replication and/or expression of nucleic acids to which they are linked in a host cell such as a eukaryotic and/or prokaryotic cell. Vectors capable of directing the expression of operatively linked genes are referred to herein as "expression vectors."

Detailed Description of the Invention

0034The invention relates to fusion proteins comprising Y. pestis antigens operably linked a thermostable protein (e.g. lichenase). The invention relates to methods of production of provided antigens, including but not limited to, production in plant systems. Further, the invention relates to vaccine compositions comprising antigens and fusion proteins in accordance with the invention. Still further provided are methods of inducing immune response against Y. pestis infection in a subject comprising administering vaccine compositions in accordance with the invention to a subject.

Yersinia pestis

Antigens

0035Yersinia pestis (also known as Pasteurella pestis) is a Gram-negative rod-shaped bacterium belonging to the family Enterobacteriaceae. It is a facultative anaerobe with bipolar staining (giving it a safety pin appearance). Similar to other Yersinia members, it tests negative for urease, lactose fermentation, and indole. Y. pestis can infect humans and other animals. Human Y. pestis infection takes three main forms: pneumonic, septicemic, and bubonic. All three forms have been responsible for high mortality rates in epidemics throughout human history, including the Black Death (a bubonic plague) that accounted for the death of approximately one-third of the European population in 1347 to 1353. During many of these epidemics, Y. pestis was transmitted by fleas infesting rats.

0036Three biovars of Y. pestis are known, each thought to correspond to one of the historical pandemics of bubonic plague. Biovar Antiqua is thought to correspond to the Plague of Justinian; it is not known whether this biovar also corresponds to earlier, smaller epidemics of bubonic plague, or whether these were even truly bubonic plague. Biovar Medievalis is thought to correspond to the Black Death. Biovar Orientalis is thought to correspond to the Third Pandemic and the majority of modem outbreaks of plague.

0037The complete genomic sequence is available for two of the three sub-species of Y. pestis: strain KIM (of biovar Medievalis) (<nplcit id="ncit0002" npl-type="s"><text>Deng et al., 2002, J. Bacteriol., 184:4601-11</text></nplcit>) and strain CO92 (of biovar Orientalis, obtained from a clinical isolate in the United States) (<nplcit id="ncit0003" npl-type="s"><text>Parkhill et al., 2001, Nature, 413:523-7</text></nplcit>). As of 2006, the genomic sequence of a strain of biovar Antiqua has been recently completed (<nplcit id="ncit0004" npl-type="s"><text>Chain et al., 2006, J. Bacterial., 188:4453-63</text></nplcit>). The chromosome of strain KIM is 4,600,755 base pairs (bp) long; the chromosome of strain CO92 is 4,653,728 bp long. Like its cousins Y. pseudotuberculosis and Y. enterocolitica, Y. pestis is host to the plasmid pCD1. In addition, it also hosts two other plasmids, pPCP1 and pMT1, which are not carried by the other Yersinia species. Together, these plasmids, and a pathogenicity island called HPI, encode several proteins which are thought to cause pathogenesis. Among other things, these virulence factors are involved in bacterial adhesion and injection of proteins into the host cell, invasion of bacteria into the host cell, and acquisition and binding of iron harvested from red blood cells.

0038Y. pestis is thought to be descendant from Y. pseudotuberculosis, differing only in the presence of specific virulence plasmids. For example, Y. pestis LcrV sequences are typically between about 90% - about 100% identical (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical) to LcrV sequences from Y. pseudotuberculosis. Y. pestis LcrV sequences are typically between about 90% - about 100% identical (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical) to LcrV sequences from Y. enterocolitica. Thus, the present invention encompasses the recognition that Y. pestis antigens may be useful for conferring protectivity and/or mounting an immune response against multiple Yersinia species, including Y. pestis, Y. pseudotuberculosis, and/or Y. enterocolitica.

0039The traditional first line treatment for Y. pestis has been streptomycin, chloramphenicol, tetracycline, and fluoroquinolones. In some cases, doxycycline or gentamicin might be useful to treat Y. pestis infection. Antibiotic treatment alone is insufficient for some patients, who may also require circulatory, ventilator, or renal support. Prior to the present invention, no plant-produced Y. pestis vaccine has been shown to be safe and effective in humans or non-human primates (<nplcit id="ncit0005" npl-type="s"><text>Alvarez et al., 2006, Vaccine, 24:2477-90</text></nplcit>; and <nplcit id="ncit0006" npl-type="s"><text>Santi et al., 2006, Proc. Natl. Acad. Sci., USA, 103:861-6</text></nplcit>; <nplcit id="ncit0007" npl-type="s"><text>Williamson et al., Infect. Immun., 2005, 73:3598-608</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>Anderson et al., 1996, Infect. Immun., 64:4580-5</text></nplcit>; <nplcit id="ncit0009" npl-type="s"><text>Andrews et al., 1996, Infect. Immun., 64:2180-7</text></nplcit>; <nplcit id="ncit0010" npl-type="s"><text>Williamson et al., 2000, Vaccine, 19:566-71</text></nplcit>; <nplcit id="ncit0011" npl-type="s"><text>Williamson et al., 1995, FEMS Immunol. Med. Microbiol., 12:223-30</text></nplcit>; and <nplcit id="ncit0012" npl-type="s"><text>Heath et al., 1998, Vaccine, 16:1131-7</text></nplcit>) and plant-produced vaccines were shown to confer protection to monkeys (<nplcit id="ncit0013" npl-type="s"><text>Mett et al. 2007, Vaccine, 25:3014-3017</text></nplcit>).

0040Y. pestis antigen proteins in accordance with the disclosure include any immunogenic protein or peptide capable of eliciting an immune response against Y. pestis. Generally, immunogenic proteins of interest include Y. pestis antigens (e.g., Y. pestis proteins, fusion proteins, etc.), immunogenic portions thereof, or immunogenic variants thereof and combinations of any of the foregoing.

0041Any Y. pestis protein can be produced and utilized as an antigen. Typically, Y. pestis proteins (i.e. full-length proteins, portions, fragments, and/or domains thereof, peptides, etc.) that are useful as antigens are not substantially identical and/or homologous to proteins which are expressed by the animal being vaccinated. In some aspects, Y. pestis proteins are less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% identical and/or homologous to proteins which are expressed by the animal being vaccinated. In some aspects, a particular Y. pestis protein may have portions and/or domains that are substantially identical and/or homologous to proteins which are expressed by the animal being vaccinated as well as portions and/or domains that are not substantially identical and/or homologous to proteins which are expressed by the animal being vaccinated. In some aspects, proteins and/or peptides to be used in accordance with the present invention are protein portions and/or domains that are not substantially identical and/or homologous to proteins which are expressed by the animal being vaccinated that have been separated and/or isolated from protein portions and/or domains that are substantially identical and/or homologous to proteins which are expressed by the animal being vaccinated.

0042Y. pestis antigens for use in accordance with the present disclosure may include full-length Y. pestis proteins or portions (i.e. fragments, domains, etc.) of Y. pestis proteins, and/or fusion proteins comprising full-length Y. pestis proteins or portions of Y. pestis proteins. Where portions of Y. pestis proteins are utilized, whether alone or in fusion proteins, such portions retain immunological activity (e.g., cross-reactivity with anti-Y. pestis antibodies). The present invention relates to two Y. pestis antigens that are of interest for developing a vaccine against Y. pestis: the anti-phagocytic capsular envelope glycoprotein (F1) and the low calcium-response V (LcrV) protein. Additional antigens (e.g., proteins, lipoproteins, glycoproteins, proteoglycans, and/or peptidoglycans associated with cell membranes and/or cell surfaces; surface antigens; periplasmic proteins; etc.) may be useful in production of vaccines (e.g., combination vaccines) in order to improve efficacy of immunoprotection.

0043Thus, the disclosure provides plant cells and/or plants expressing a heterologous protein, such as a Y. pestis antigen (e.g., Y. pestis protein or a fragment thereof, a fusion protein comprising a Y. pestis protein or portion thereof). A heterologous protein can comprise any Y. pestis antigen of interest, including, but not limited to F1, LcrV, or fusion proteins, portions, or combinations of F1, LcrV, a portion of F1 and/or a portion of LcrV. In some aspects, the disclosure provides plant cells and/or plants expressing a full-length heterologous protein. In some embodiments, the invention provides plant cells and/or plants expressing a portion of a heterologous protein. In some aspects, the disclosure provides plant cells and/or plants expressing multiple portions of a heterologous protein. In some aspects such multiple portions are each produced from an individual vector. In some aspects, such multiple protein portions are tandemly expressed from the same vector (i.e. a "polytope"). In some aspects, all of the multiple protein portions of a polytope are identical to one another. In some aspects, not all of the multiple protein portions are identical to one another.

0044Amino acid sequences of a variety of different Y. pestis proteins (e.g., F1 and/or LcrV) are known in the art and are available in public databases such as GenBank. In some aspects, Y. pestis antigens comprise F1 protein and/or a characteristic portion thereof. In some aspects, F1 protein is variable at amino acid position 48 In some aspects, the amino acid at position 48 is alanine. In some aspects, the amino acid at position 48 is serine. In some aspects, multiple F1 protein variants differ only at position 48.

0045Exemplary full-length amino acid sequences for F1 protein which comprise an alanine at residue 48 include, but are not limited to, amino acid sequences as set forth in GenBank accession numbers NP_395430; AAM94402.1; AAM94401.1; AAM94400.1; AAM94399.1; AAM94398.1; AAM94397.1; AAM94396.1; AAM94395.1; NP_995523.1; AAS58714.1; CAA43966.1; NP_857881.1; AAC82758.1; YP_636639.1; and YP_636755.1. In some aspects, an F1 protein comprising an alanine at residue 48 may be obtained, isolated, purified, and/or derived from Y. pestis strains CO92, Antiqua, Microtus, Str.91001, KIM, Nepal 516, and/or FV1.

0046One exemplary full length protein sequence for F1 protein comprising an alanine at position 48 is: <img file="EP2178558B1_D0001.tif" /> The bold, underlined sequence above (i.e., MKK...ANA) corresponds to a signal sequence. The bold, underlined alanine residue at position 48 corresponds to a site of variability in the F1 protein.

0047In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO: 1.

0048In some aspects, a Y. pestis antigen comprises an amino acid sequence which comprises about 100 contiguous amino acids of SEQ ID NO: 1. In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 100 amino acids of SEQ ID NO: 1.

0049One exemplary full-length nucleotide sequence encoding F1 protein comprising an alanine at position 48 corresponds to GenBank accession number NC_003134 (83368..85869): <img file="EP2178558B1_D0002.tif" /> The bold, underlined sequence above (i.e., ATG...GCG) corresponds to the nucleotide sequence encoding a signal sequence of F1 protein. The bold, underlined codon (i.e., GCT) corresponds to the nucleotide sequence encoding the alanine residue at position 48.

0050In some aspects, full length F1 protein does not comprise the signal sequence. One exemplary full length protein sequence for F1 protein comprising an alanine at position 48 but not comprising a signal sequence is: <img file="EP2178558B1_D0003.tif" /> The bold, underlined alanine residue at position 48 corresponds to a site of variability in the F1 protein.

0051In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO: 3.

0052In some aspects, a Y. pestis antigen comprises an amino acid sequence which comprises about 100 contiguous amino acids of SEQ ID NO: 3. In some embodiments, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 100 amino acids of SEQ ID NO: 3.

0053One exemplary full-length nucleotide sequence encoding F1 protein comprising an alanine at position 48 but not comprising a signal sequence is:: <img file="EP2178558B1_D0004.tif" /> The bold, underlined codon (i.e., GCT) corresponds to the nucleotide sequence encoding the alanine residue at position 48.

0054Exemplary full-length amino acid sequences for F1 protein which comprise a serine at residue 48 include, but are not limited to, amino acid sequences as set forth in GenBank accession numbers YP_093952, YP_001154728.1, CAG27478.1, and/or ABP42491.1. In some aspects, an F1 protein comprising a serine at residue 48 may be obtained, isolated, purified, and/or derived from Y. pestis strains Pestoides, CA 88-4125, and/or EV.

0055One exemplary full length protein sequence for F1 protein comprising a serine at position 48 is: <img file="EP2178558B1_D0005.tif" /> The bold, underlined sequence above (i.e., MKK...ANA) corresponds to a signal sequence. The bold, underlined serine residue at position 48 corresponds to a site of variability in the F1 protein.

0056In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO: 5.

0057In some aspects, a Y. pestis antigen comprises an amino acid sequence which comprises about 100 contiguous amino acids of SEQ ID NO: 5. In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 100 amino acids of SEQ ID NO: 5.

0058One exemplary full-length nucleotide sequence encoding F1 protein comprising an serine at position 48 corresponds to GenBank accession number NC_006323.1: <img file="EP2178558B1_D0006.tif" /><img file="EP2178558B1_D0007.tif" /> The bold, underlined sequence above (i.e., ATG...GCG) corresponds to the nucleotide sequence encoding a signal sequence of F1 protein. The bold, underlined codon (i.e., TCT) corresponds to the nucleotide sequence encoding the serine residue at position 48.

0059In some aspects, full length F1 protein does not comprise the signal sequence. One exemplary full length protein sequence for F1 protein comprising an alanine at position 48 but not comprising a signal sequence is: <img file="EP2178558B1_D0008.tif" /> The bold, underlined serine residue at position 48 corresponds to a site of variability in the F1 protein.

0060In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO: 7.

0061In some aspects, a Y. pestis antigen comprises an amino acid sequence which comprises about 100 contiguous amino acids of SEQ ID NO: 7. In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 100 amino acids of SEQ ID NO: 7.

0062One exemplary full-length nucleotide sequence encoding F1 protein comprising an serine at position 48 but not comprising a signal sequence is: <img file="EP2178558B1_D0009.tif" /><img file="EP2178558B1_D0010.tif" /> The bold, underlined codon (i.e., TCT) corresponds to the nucleotide sequence encoding the serine residue at position 48.

0063In certain aspects, full length F1 protein is utilized in vaccine compositions in accordance with the disclosure. In some aspects, one or more portions and/or domains of F1 protein is used. In certain aspects, two or three or more portions and/or domains are utilized, as one or more separate polypeptides or linked together in one or more fusion polypeptides.

0064In some aspects, Y. pestis antigens comprise LcrV protein and/or a characteristic portion thereof. Exemplary full-length amino acid sequences for LcrV protein include, but are not limited to, amino acid sequences as set forth in GenBank accession numbers NP_863514.1; NP_783665.1; NP_052392.1; AAK69213.1; AAN37531.1; AAD16815.1; YP_068466.1; CAF25400.1; P0C556.1; NP_995380.1; AAS58571.1; ZP_02318603.1; ZP_02314654.1; ZP_02314147.1; ZP_02314145.1; ZP_02307430.1; EDR63976.1; EDR60080.1; EDR55652.1; EDR55650.1; EDR55212.1; ZP_02240571.1; EDR48750.1; EDR41684.1; ZP_02232674.1; ZP_02228629.1; ZP_02223652.1; EDR37557.1; EDR30648.1; YP_001604463.1; ABX88711.1; CAB54908.1; ABF48194.1; ABF48193.1; ABF48192.1; ABF48191.1; ABF48190.1; ABF48189.1; NP_395165.1; YP_001293940.1; NP_857946.1; NP_857751.1; ABR68791.1; ABR68790.1; ABR68789.1; ABR68788.1; ABR14856.1; AAC69799.1; AAC62574.1; AAF64077.1; A4TSQ1.1; YP_001004069.1; CAL10039.1; P23994.1; AAA27645.1; AAF64076.1; YP_636823.1; ABG16274.1; ABP42325.1; YP_001154615.1; ABB16313.1; YP_001874676.1; ACC91219.1; and/or ABI97154.1 (SEQ ID NOs: 38 - 102, respectively; see <figref idref="f0001 f0002 f0003 f0004 f0005 f0006 f0007 f0008 f0009 f0010 f0011 f0012 f0013 f0014 f0015 f0016 f0017 f0018 f0019 f0020 f0021 f0022 f0023 f0024">Figure 1</figref>). In some aspects, an LcrV protein may be obtained, isolated, purified, and/or derived from Y. pestis strains, for example, from Antiqua strain E1979001, Antiqua strain B42003004, Ulegeica, CA88-4125, KIM, Orientalis strain MG05-1020, and/or Mediaevalis strain K1973002. <figref idref="f0001 f0002 f0003 f0004 f0005 f0006 f0007 f0008 f0009 f0010 f0011 f0012 f0013 f0014 f0015 f0016 f0017 f0018 f0019 f0020 f0021 f0022 f0023 f0024">Figure 1</figref> presents multiple LcrV protein variants from different Y. pestis strains aligned with the sequence of LcrV that was used in the production of antigen constructs in the Exemplification ("LcrV.pro," SEQ ID NO: 103).

0065One exemplary full length protein sequence for LcrV protein is: <img file="EP2178558B1_D0011.tif" />

0066In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO: 9.

0067In some aspects, a Y. pestis antigen comprises an amino acid sequence which comprises about 100 contiguous amino acids of SEQ ID NO: 9. In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 100 amino acids of SEQ ID NO: 9.

0068One exemplary full-length nucleotide sequence encoding LcrV protein is: <img file="EP2178558B1_D0012.tif" /><img file="EP2178558B1_D0013.tif" />

0069In certain aspects, full length LcrV protein is utilized in vaccine compositions in accordance with the disclosure. In some aspects one or more portions and/or domains of LcrV protein is used. In certain aspects, two or three or more portions and/or domains are utilized, as one or more separate polypeptides or linked together in one or more fusion polypeptides.

0070In some aspects, a Y. pestis antigen composition comprises a fusion protein. In some aspects, the fusion protein may contain two or more identical antigen proteins. In some aspects, the fusion protein may contain two or more distinct antigen proteins. In the claimed invention, a Y. pestis antigen composition comprises a fusion of F 1 and LcrV proteins.

0071In the claimed invention, a fusion of F 1 and LcrV proteins has an amino acid sequence that is identical to that set forth in SEQ ID NO: 27. In some embodiments, a Y. pestis antigen comprises an amino acid sequence which is about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO: 27.

0072In some aspects, a fusion of F1 and LcrV proteins comprises an amino acid sequence that is identical to that set forth in SEQ ID NO: 33. In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO: 33.

0073In some aspects, a Y. pestis antigen comprises an amino acid sequence which comprises about 100 contiguous amino acids of SEQ ID NO: 33. In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 100 amino acids of SEQ ID NO: 33.

0074In some aspects, a fusion of F1 and LcrV proteins comprises an amino acid sequence that is identical to that set forth in SEQ ID NO: 34. In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to SEQ ID NO: 34.

0075In some aspects, a Y. pestis antigen comprises an amino acid sequence which comprises about 100 contiguous amino acids of SEQ ID NO: 34. In some aspects, a Y. pestis antigen comprises an amino acid sequence which is about 60% identical, about 7% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 100 amino acids of SEQ ID NO: 34.

0076In some aspects, a fusion of F1 and LcrV proteins comprises amino acid sequences that are identical to those set forth in SEQ ID NOs: 33 and 34.

0077In some aspects, a Y. pestis antigen comprises amino acid sequences which are greater than 60% identical, greater than 7% identical, greater than 80% identical, greater than 85% identical, greater than 90% identical, greater than 91% identical, greater than 92% identical, greater than 93% identical, greater than 94% identical, greater than 95% identical, greater than 96% identical, greater than 97% identical, greater than 98% identical, greater than 99% identical, or 100% identical to SEQ ID NOs: 33 and 34.

0078In some aspects, a Y. pestis antigen comprises amino acid sequences which comprise about 100 contiguous amino acids of each of SEQ ID NOs: 33 and 34. In some aspects, a Y. pestis antigen comprises amino acid sequences which are greater than 60% identical, greater than 7% identical, greater than 80% identical, greater than 85% identical, greater than 90% identical, greater than 91% identical, greater than 92% identical, greater than 93% identical, greater than 94% identical, greater than 95% identical, greater than 96% identical, greater than 97% identical, greater than 98% identical, greater than 99% identical, or 100% identical to contiguous stretches of about 100 amino acids of each of SEQ ID NOs: 33 and 34.

Production of

Yersinia pestis

Antigens

0079In accordance with the present invention, Y. pestis antigens (including Y. pestis protein(s), portions, fragments, domains, variants, and/or fusions thereof) may be produced in any desirable system; production is not limited to plant systems. Vector constructs and expression systems are well known in the art and may be adapted to incorporate use of Y. pestis antigens provided herein. For example, Y. pestis antigens (including Y. pestis protein(s), portions, fragments, domains, variants, and/or fusions thereof) can be produced in known expression systems, including mammalian cell systems, transgenic animals, microbial expression systems, insect cell systems, and plant systems, including transgenic and transient plant systems. Particularly where Y. pestis antigens are produced as fusion proteins, it may be desirable to produce such fusion proteins in non-plant systems.

0080In some embodiments, Y. pestis antigens are desirably produced in plant systems. Plants are relatively easy to manipulate genetically, and have several advantages over alternative sources such as human fluids, animal cell lines, recombinant microorganisms and transgenic animals. Plants have sophisticated post-translational modification machinery for proteins that is similar to that of mammals (although it should be noted that there are some differences in glycosylation patterns between plants and mammals). This enables production of bioactive reagents in plant tissues. Also, plants can economically produce very large amounts of biomass without requiring sophisticated facilities. Thus, protein production in plants typically requires a much lower capital investment and cost-of-goods than does protein production using other systems. Moreover, plants are not subject to contamination with animal pathogens. Like liposomes and microcapsules, plant cells are expected to provide protection for passage of antigen to the gastrointestinal tract. In many instances, production of proteins in plants leads to improved consumer safety.

0081Plants may be utilized for production of heterologous proteins via use of various production systems. One such system includes use of transgenic/genetically-modified plants where a gene encoding target product is permanently incorporated into the genome of the plant. Transgenic systems may generate crop production systems. A variety of foreign proteins, including many of mammalian origin and many vaccine candidate antigens, have been expressed in transgenic plants and shown to have functional activity (<nplcit id="ncit0014" npl-type="s"><text>Tacket et al., 2000, J. Infect. Dis., 182:302</text></nplcit>; and <nplcit id="ncit0015" npl-type="s"><text>Thanavala et al., 2005, Proc. Natl. Acad. Sci., USA, 102:3378</text></nplcit>). Additionally, administration of unprocessed transgenic plants expressing hepatitis B major surface antigen to non-immunized human volunteers resulted in production of immune response (Kapusta et al., 1999, FASEB J., 13:1796).

0082One system for expressing polypeptides in plants utilizes plant viral vectors engineered to express foreign sequences (e.g., transient expression). This approach allows for use of healthy non-transgenic plants as rapid production systems. Thus, genetically engineered plants and plants infected with recombinant plant viruses can serve as "green factories" to rapidly generate and produce specific proteins of interest. Plant viruses have certain advantages that make them attractive as expression vectors for foreign protein production. Several members of plant RNA viruses have been well characterized, and infectious cDNA clones are available to facilitate genetic manipulation. Once infectious viral genetic material enters a susceptible host cell, it replicates to high levels and spreads rapidly throughout the entire plant. There are several approaches to producing target polypeptides using plant viral expression vectors, including incorporation of target polypeptides into viral genomes. One approach involves engineering coat proteins of viruses that infect bacteria, animals or plants to function as carrier molecules for antigenic peptides. Such carrier proteins have the potential to assemble and form recombinant virus-like particles displaying desired antigenic epitopes on their surface. This approach allows for time-efficient production of vaccine candidates, since the particulate nature of a vaccine candidate facilitates easy and cost-effective recovery from plant tissue. Additional advantages include enhanced target-specific immunogenicity, the potential to incorporate multiple vaccine determinants, and ease of formulation into vaccines that can be delivered nasally, orally or parenterally. As an example, spinach leaves containing recombinant plant viral particles carrying epitopes of virus fused to coat protein have generated immune response upon administration (<nplcit id="ncit0016" npl-type="s"><text>Modelska et al., 1998, Proc. Natl. Acad. Sci., USA, 95:2481</text></nplcit>; and <nplcit id="ncit0017" npl-type="s"><text>Yusibov et al., 2002, Vaccine, 19/20:3155</text></nplcit>).

Plant Expression Systems

0083Any plant susceptible to incorporation and/or maintenance of heterologous nucleic acid and capable of producing heterologous protein may be utilized in accordance with the present invention. In general, it will often be desirable to utilize plants that are amenable to growth under defined conditions, for example in a greenhouse and/or in aqueous systems. It may be desirable to select plants that are not typically consumed by human beings or domesticated animals and/or are not typically part of the human food chain, so that they may be grown outside without concern that expressed polynucleotide may be undesirably ingested. In some embodiments, however, it will be desirable to employ edible plants. In particular embodiments, it will be desirable to utilize plants that accumulate expressed polypeptides in edible portions of a plant.

0084Often, certain desirable plant characteristics will be determined by the particular polynucleotide to be expressed. To give but a few examples, when a polynucleotide encodes a protein to be produced in high yield (as will often be the case, for example, when antigen proteins are to be expressed), it will often be desirable to select plants with relatively high biomass (e.g., tobacco, which has additional advantages that it is highly susceptible to viral infection, has a short growth period, and is not in the human food chain). Where a polynucleotide encodes antigen protein whose full activity requires (or is inhibited by) a particular post-translational modification, the ability (or inability) of certain plant species to accomplish relevant modification (e.g., a particular glycosylation) may direct selection. For example, plants are capable of accomplishing certain post-translational modifications (e.g., glycosylation), however, plants will not generate siaylation sialyation patterns which are found in mammalian post-translational modification. Thus, plant production of antigen may result in production of a different entity than the identical protein sequence produced in alternative systems.

0085In certain embodiments, crop plants, or crop-related plants are utilized. In certain specific embodiments, edible plants are utilized.

0086Plants for use in accordance with the present invention include Angiosperms, Bryophytes (e.g., Hepaticae, Musci, etc.), Pteridophytes (e.g., ferns, horsetails, lycopods), Gymnosperms (e.g., conifers, cycase, Ginko, Gnetales), and Algae (e.g., Chlorophyceae, Phaeophyceae, Rhodophyceae, Myxophyceae, Xanthophyceae, and Euglenophyceae). Exemplary plants are members of the family Leguminosae (Fabaceae; e.g., pea, alfalfa, soybean); Gramineae (Poaceae; e.g., corn, wheat, rice); Solanaceae, particularly of the genus Lycopersicon (e.g., tomato), Solanum (e.g., potato, eggplant), Capsium (e.g., pepper), or Nicotiana (e.g., tobacco); Umbelliferae, particularly of the genus Daucus (e.g., carrot), Apium (e.g., celery), or Rutaceae (e.g., oranges); Compositae, particularly of the genus Lactuca (e.g., lettuce); Brassicaceae (Cruciferae), particularly of the genus Brassica or Sinapis. In certain aspects, plants in accordance with the invention may be plants of the Brassica or Arabidopsis genus. Some exemplary Brassicaceae family members include Brassica campestris, B. carinata, B. juncea, B. napus, B. nigra, B. oleraceae, B. tournifortii, Sinapis alba, and Raphanus sativus. Some suitable plants that are amendable to transformation and are edible as sprouted seedlings include alfalfa, mung bean, radish, wheat, mustard, spinach, carrot, beet, onion, garlic, celery, rhubarb, a leafy plant such as cabbage or lettuce, watercress or cress, herbs such as parsley, mint, or clovers, cauliflower, broccoli, soybean, lentils, edible flowers such as sunflower, peas, etc.

Introducing Vectors into Plants

0087In general, vectors may be delivered to plants according to known techniques. For example, vectors themselves may be directly applied to plants (e.g., via abrasive inoculations, mechanized spray inoculations, vacuum infiltration, particle bombardment, or electroporation). Alternatively or additionally, virions may be prepared (e.g., from already infected plants), and may be applied to other plants according to known techniques.

0088A wide variety of viruses are known that infect various plant species, and can be employed for polynucleotide expression according to the present invention (see, for example, in <nplcit id="ncit0018" npl-type="b"><text>The Classification and Nomenclature of Viruses, "Sixth Report of the International Committee on Taxonomy of Viruses" (Ed. Murphy et al.), Springer Verlag: New York, 1995</text></nplcit>; <nplcit id="ncit0019" npl-type="b"><text>Grierson et al., Plant Molecular Biology, Blackie, London, pp. 126-146, 1984</text></nplcit>; <nplcit id="ncit0020" npl-type="b"><text>Gluzman et al., Communications in Molecular Biology: Viral Vectors, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 172-189, 1988</text></nplcit>; and Mathew, Plant Viruses Online (http://image.fs.uidaho.edu/vide/). In certain embodiments, rather than delivering a single viral vector to a plant cell, multiple different vectors are delivered which, together, allow for replication (and, optionally cell-to-cell and/or long distance movement) of viral vector(s). Some or all proteins may be encoded by the genome of transgenic plants. In certain aspects, described in further detail herein, these systems include one or more viral vector components.

0089Vector systems that include components of two heterologous plant viruses in order to achieve a system that readily infects a wide range of plant types and yet poses little or no risk of infectious spread. An exemplary system has been described previously (see, e.g., <patcit id="pcit0002" dnum="WO0025574A"><text>PCT Publication WO 00/25574</text></patcit> and <patcit id="pcit0003" dnum="US20050026291A"><text>U.S. Patent Publication 2005/0026291</text></patcit>). As noted herein, in particular aspects of the invention, viral vectors are applied to plants (e.g., plant, portion of plant, sprout, etc.), for example, through infiltration or mechanical inoculation, spray, etc. Where infection is to be accomplished by direct application of a viral genome to a plant, any available technique may be used to prepare the genome. For example, many viruses that are usefully employed in accordance with the present invention have ssRNA genomes. ssRNA may be prepared by transcription of a DNA copy of the genome, or by replication of an RNA copy, either in vivo or in vitro. Given the readily availability of easy-to-use in vitro transcription systems (e.g., SP6, T7, reticulocyte lysate, etc.), and also the convenience of maintaining a DNA copy of an RNA vector, it is expected that ssRNA vectors will often be prepared by in vitro transcription, particularly with T7 or SP6 polymerase.

0090In certain embodiments, rather than introducing a single viral vector type into a plant, multiple different viral vectors are introduced. Such vectors may, for example, trans-complement each other with respect to functions such as replication, cell-to-cell movement, and/or long distance movement. Vectors may contain different polynucleotides encoding Y. pestis antigen in accordance with the invention. Selection for plant(s) or portions thereof that express multiple polypeptides encoding one or more Y. pestis antigen(s) may be performed as described above for single polynucleotides or polypeptides.

Plant Tissue Expression Systems

0091As discussed above, in accordance with the present invention, Y. pestis antigens may be produced in any desirable system. Vector constructs and expression systems are well known in the art and may be adapted to incorporate use of Y. pestis antigens provided herein. For example, transgenic plant production is known and generation of constructs and plant production may be adapted according to known techniques in the art. In some embodiments, transient expression systems in plants are desirable. Two of these systems include production of clonal roots and clonal plant systems, and derivatives thereof, as well as production of sprouted seedlings systems.

Clonal Plants

0092Clonal roots maintain RNA viral expression vectors and stably produce target protein uniformly in an entire root over extended periods of time and multiple subcultures. In contrast to plants, where a target gene is eliminated via recombination during cell-to-cell or long distance movement, in root cultures the integrity of a viral vector is maintained and levels of target protein produced over time are similar to those observed during initial screening. Clonal roots allow for ease of production of heterologous protein material for oral formulation of antigen and vaccine compositions. Methods and reagents for generating a variety of clonal entities derived from plants which are useful for production of antigen (e.g., antigen proteins in accordance with the invention) have been described previously and are known in the art (see, for example, <patcit id="pcit0004" dnum="WO0581905A"><text>PCT Publication WO 05/81905</text></patcit>). Clonal entities include clonal root lines, clonal root cell lines, clonal plant cell lines, and clonal plants capable of production of antigen (e.g., antigen proteins in accordance with the invention). The invention further provides methods and reagents for expression of antigen polynucleotide and polypeptide products in clonal cell lines derived from various plant tissues (e.g., roots, leaves), and in whole plants derived from single cells (clonal plants). Such methods are typically based on use of plant viral vectors of various types.

0093For example, in one aspect, the disclosure provides methods of obtaining a clonal root line that expresses a polynucleotide encoding a Y. pestis antigen comprising steps of: (i) introducing a viral vector that comprises a polynucleotide encoding a Y. pestis antigen into a plant or portion thereof; and (ii) generating one or more clonal root lines from a plant. Clonal root lines may be generated, for example, by infecting a plant or plant portion (e.g., a harvested piece of leaf) with an Agrobacterium (e.g., A. rhizogenes) that causes formation of hairy roots. Clonal root lines can be screened in various ways to identify lines that maintain virus, lines that express a polynucleotide encoding a Y. pestis antigen at high levels, etc. The disclosure Further provides clonal root lines, and further encompasses methods of expressing polynucleotides and producing polypeptide(s) encoding Y. pestis antigen(s) using clonal root lines.

0094The disclosure further provides methods of generating a clonal root cell line that expresses a polynucleotide encoding a Y. pestis antigen comprising steps of: (i) generating a clonal root line, cells of which contain a viral vector whose genome comprises a polynucleotide encoding a Y. pestis antigen; (ii) releasing individual cells from a clonal root line; and (iii) maintaining cells under conditions suitable for root cell proliferation. The disclosure provides clonal root cell lines and methods of expressing polynucleotides and producing polypeptides using clonal root cell lines.

0095In one aspect, the disclosure provides methods of generating a clonal plant cell line that expresses a polynucleotide encoding a Y. pestis antigen in accordance with the invention comprising steps of: (i) generating a clonal root line, cells of which contain a viral vector whose genome comprises a polynucleotide encoding a Y. pestis antigen; (ii) releasing individual cells from a clonal root line; and (iii) maintaining cells in culture under conditions appropriate for plant cell proliferation. The disclosure further provides methods of generating a clonal plant cell line that expresses a polynucleotide encoding a Y. pestis antigen comprising steps of: (i) introducing a viral vector that comprises a polynucleotide encoding a Y. pestis antigen into cells of a plant cell line maintained in culture; and (ii) enriching for cells that contain viral vector. Enrichment may be performed, for example, by (i) removing a portion of cells from culture; (ii) diluting removed cells so as to reduce cell concentration; (iii) allowing diluted cells to proliferate; and (iv) screening for cells that contain viral vector. Clonal plant cell lines may be used for production of a Y. pestis antigen in accordance with the present invention

0096The disclosure includes a number of methods for generating clonal plants, cells of which contain a viral vector that comprises a polynucleotide encoding Y. pestis antigen in accordance with the invention. For example, the disclosure provides methods of generating a clonal plant that expresses a polynucleotide encoding Y. pestis antigen comprising steps of: (i) generating a clonal root line, cells of which contain a viral vector whose genome comprises a polynucleotide encoding Y. pestis antigen; (ii) releasing individual cells from a clonal root line; and (iii) maintaining released cells under conditions appropriate for formation of a plant. The disclosure further provides methods of generating a clonal plant that expresses a polynucleotide encoding Y. pestis antigen comprising steps of: (i) generating a clonal plant cell line, cells of which contain a viral vector whose genome comprises a polynucleotide encoding a Y. pestis antigen; and (ii) maintaining cells under conditions appropriate for formation of a plant. In general, clonal plants can express any polynucleotide encoding a Y. pestis antigen. Such clonal plants can be used for production of an antigen polypeptide.

0097As noted above, the present disclosure provides systems for expressing a polynucleotide or polynucleotide(s) encoding Y. pestis antigen(s) in clonal root lines, clonal root cell lines, clonal plant cell lines (e.g., cell lines derived from leaf, stem, etc.), and in clonal plants. A polynucleotide encoding a Y. pestis antigen is introduced into an ancestral plant cell using a plant viral vector whose genome includes polynucleotide encoding a Y. pestis antigen operably linked to (i.e., under control of) a promoter. A clonal root line or clonal plant cell line is established from a cell containing virus according to any of several techniques further described below. A plant virus vector or portions thereof can be introduced into a plant cell by infection, by inoculation with a viral transcript or infectious cDNA clone, by electroporation, by T-DNA mediated gene transfer, etc.

0098The following sections describe methods for generating clonal root lines, clonal root cell lines, clonal plant cell lines, and clonal plants that express a polynucleotide encoding a Y. pestis antigen in accordance with the invention are then described. A "root line" is distinguished from a "root cell line" in that a root line produces actual root-like structures or roots while a root cell line consists of root cells that do not form root-like structures. Use of the term "line" is intended to indicate that cells of a line can proliferate and pass genetic information on to progeny cells. Cells of a cell line typically proliferate in culture without being part of an organized structure such as those found in an intact plant. Use of the term "root line" is intended to indicate that cells in a root structure can proliferate without being part of a complete plant. It is noted that the term "plant cell" encompasses root cells. However, to distinguish methods in accordance with the invention for generating root lines and root cell lines from those used to directly generate plant cell lines from non-root tissue (as opposed to generating clonal plant cell lines from clonal root lines or clonal plants derived from clonal root lines), the terms "plant cell" and "plant cell line" as used herein generally refer to cells and cell lines that consist of non-root plant tissue. Plant cells can be, for example, leaf, stem, shoot, flower part, etc. It is noted that seeds can be derived from clonal plants generated as derived herein. Such seeds may contain viral vector as will plants obtained from such seeds. Methods for obtaining seed stocks are well known in the art (see, for example, <patcit id="pcit0005" dnum="US2004093643A"><text>U.S Patent Publication 2004/093643</text></patcit>).

Clonal Root Lines

0099The present disclosure provides systems for generating a clonal root line in which a plant viral vector is used to direct expression of a polynucleotide encoding a Y. pestis antigen in accordance with the invention. One or more viral expression vector(s) including a polynucleotide encoding a Y. pestis antigen operably linked to a promoter is introduced into a plant or a portion thereof according to any of a variety of known methods. For example, plant leaves can be inoculated with viral transcripts. Vectors themselves may be directly applied to plants (e.g., via abrasive inoculations, mechanized spray inoculations, vacuum infiltration, particle bombardment, or electroporation). Alternatively or additionally, virions may be prepared (e.g., from already infected plants), and may be applied to other plants according to known techniques.

0100Where infection is to be accomplished by direct application of a viral genome to a plant, any available technique may be used to prepare viral genome. For example, many viruses that are usefully employed in accordance with the present invention have ssRNA genomes. ssRNA may be prepared by transcription of a DNA copy of the genome, or by replication of an RNA copy, either in vivo or in vitro. Given the readily available, easy-to-use in vitro transcription systems (e.g., SP6, T7, reticulocyte lysate, etc.), and also the convenience of maintaining a DNA copy of an RNA vector, it is expected that ssRNA vectors will often be prepared by in vitro transcription, particularly with T7 or SP6 polymerase. Infectious cDNA clones can be used. Agrobacterially-mediated gene transfer can be used to transfer viral nucleic acids such as viral vectors (either entire viral genomes or portions thereof) to plant cells using, e.g., agroinfiltration, according to methods known in the art.

0101A plant or plant portion may then be then maintained (e.g., cultured or grown) under conditions suitable for replication of viral transcript. In certain embodiments virus spreads beyond the initially inoculated cell, e.g., locally from cell to cell and/or systemically from an initially inoculated leaf into additional leaves. However, in some embodiments, virus does not spread. Thus viral vector may contain genes encoding functional MP and/or CP, but may be lacking one or both of such genes. In general, viral vector is introduced into (infects) multiple cells in the plant or portion thereof.

0102Following introduction of viral vector into a plant, leaves are harvested. In general, leaves may be harvested at any time following introduction of a viral vector. However, it may be desirable to maintain a plant for a period of time following introduction of a viral vector into a plant, e.g., a period of time sufficient for viral replication and, optionally, spread of virus from cells into which it was initially introduced. A clonal root culture (or multiple cultures) is prepared, e.g., by known methods further described below.

0103In general, any available method may be used to prepare a clonal root culture from a plant or plant tissue into which a viral vector has been introduced. One such method employs genes that exist in certain bacterial plasmids. These plasmids are found in various species of Agrobacterium that infect and transfer DNA to a wide variety of organisms. As a genus, Agrobacteria can transfer DNA to a large and diverse set of plant types including numerous dicot and monocot angiosperm species and gymnosperms (see, for example, <nplcit id="ncit0021" npl-type="s"><text>Gelvin, 2003, Microbiol. Mol. Biol. Rev., 67:16</text></nplcit>, and references therein). The molecular basis of genetic transformation of plant cells is transfer from bacterium and integration into plant nuclear genome of a region of a large tumor-inducing (Ti) or rhizogenic (Ri) plasmid that resides within various Agrobacterial species. This region is referred to as the T-region when present in the plasmid and as T-DNA when excised from plasmid. Generally, a single-stranded T-DNA molecule is transferred to a plant cell in naturally occurring Agrobacterial infection and is ultimately incorporated (in double-stranded form) into the genome. Systems based on Ti plasmids are widely used for introduction of foreign genetic material into plants and for production of transgenic plants.

0104Infection of plants with various Agrobacterial species and transfer of T-DNA has a number of effects. For example, A. tumefaciens causes crown gall disease while A. rhizogenes causes development of hairy roots at the site of infection, a condition known as "hairy root disease." Each root arises from a single genetically transformed cell. Thus root cells in roots are clonal, and each root represents a clonal population of cells. Roots produced by A. rhizogenes infection are characterized by a high growth rate and genetic stability (<nplcit id="ncit0022" npl-type="s"><text>Giri et al., 2000, Biotech. Adv., 18:1</text></nplcit>, and references therein). In addition, such roots are able to regenerate genetically stable plants (Giri 2000, supra).

0105In general, the present invention encompasses use of any strain of Agrobacteria, particularly A. rhizogenes strains, that is capable of inducing formation of roots from plant cells. As mentioned above, a portion of the Ri plasmid (Ri T-DNA) is responsible for causing hairy root disease. While transfer of this portion of the Ri plasmid to plant cells can conveniently be accomplished by infection with Agrobacteria harboring the Ri plasmid, the invention encompasses use of alternative methods of introducing the relevant region into a plant cell. Such methods include any available method of introducing genetic material into plant cells including, but not limited to, biolistics, electroporation, PEG-mediated DNA uptake, Ti-based vectors, etc. The relevant portions of Ri T-DNA can be introduced into plant cells by use of a viral vector. Ri genes can be included in the same vector that contains a polynucleotide encoding a Y. pestis antigen or in a different viral vector, which can be the same or a different type to that of the vector that contains a polynucleotide encoding a Y. pestis antigen. It is noted that the entire Ri T-DNA may not be required for production of hairy roots, and the invention encompasses use of portions of Ri T-DNA, provided that such portions contain sufficient genetic material to induce root formation, as known in the art. Additional genetic material, e.g., genes present within the Ri plasmid but not within T-DNA, may be transferred to a plant cell, particularly genes whose expression products facilitate integration of T-DNA into plant cell DNA.

0106In order to prepare a clonal root line in accordance with certain embodiments, harvested leaf portions are contacted with A. rhizogenes under conditions suitable for infection and transformation. Leaf portions are maintained in culture to allow development of hairy roots. Each root is clonal, i.e., cells in the root are derived from a single ancestral cell into which Ri T-DNA was transferred. A portion of such ancestral cells will contain a viral vector. Thus cells in a root derived from such an ancestral cell may contain viral vector since it will be replicated and will be transmitted during cell division. Thus a high proportion (e.g. at least 50%, at least 75%, at least 80%, at least 90%, at least 95%), all (i.e., 100%), or substantially all (e.g., at least 98%) of cells will contain viral vector. It is noted that since viral vector is inherited by daughter cells within a clonal root, movement of viral vector within the root is not necessary to maintain viral vector throughout the root. Individual clonal hairy roots may be removed from the leaf portion and further cultured. Such roots are also referred to herein as root lines. Isolated clonal roots continue to grow following isolation.

0107A variety of different clonal root lines have been generated using methods in accordance with the disclosure. These root lines were generated using viral vectors containing polynucleotide(s) encoding a Y. pestis antigen (e.g., encoding including Y. pestis protein(s), portions, fragments, domains, variants, and/or fusions thereof). Root lines were tested by western blot. Root lines displayed a variety of different expression levels of various polypeptides. Root lines displaying high expression were selected and further cultured. These root lines were subsequently tested again and shown to maintain high levels of expression over extended periods of time, indicating stability. Expression levels were comparable to or greater than expression in intact plants infected with the same viral vector used to generate clonal root lines. In addition, stability of expression of root lines was superior to that obtained in plants infected with the same viral vector. Up to 80% of such virus-infected plants reverted to wild type after 2 - 3 passages. (Such passages involved inoculating plants with transcripts, allowing infection (local or systemic) to become established, taking a leaf sample, and inoculating fresh plants that are subsequently tested for expression).

0108Root lines may be cultured on a large scale for production of antigen polypeptides as discussed further below. It is noted that clonal root lines (and cell lines derived from clonal root lines) can generally be maintained in medium that does not include various compounds, e.g., plant growth hormones such as auxins, cytokinins, etc., that are typically employed in culture of root and plant cells. This feature greatly reduces expense associated with tissue culture, and the inventors expect that it will contribute significantly to economic feasibility of protein production using plants.

0109Any of a variety of methods may be used to select clonal roots that express a polynucleotide encoding Y. pestis antigen(s). Western blots, ELISA assays, etc., can be used to detect an encoded polypeptide. In the case of detectable markers such as GFP, alternative methods such as visual screens can be performed. If a viral vector that contains a polynucleotide that encodes a selectable marker is used, an appropriate selection can be imposed (e.g., leaf material and/or roots derived therefrom can be cultured in the presence of an appropriate antibiotic or nutritional condition and surviving roots identified and isolated). Certain viral vectors contain two or more polynucleotide(s) encoding Y. pestis antigen(s), e.g., two or more polynucleotides encoding different polypeptides. If one of these is a selectable or detectable marker, clonal roots that are selected or detected by selecting for or detecting expression of a marker will have a high probability of also expressing a second polynucleotide. Screening for root lines that contain particular polynucleotides can also be performed using PCR and other nucleic acid detection methods.

0110Alternatively or additionally, clonal root lines can be screened for presence of virus by inoculating host plants that will form local lesions as a result of virus infection (e.g., hypersensitive host plants). For example, 5 mg of root tissue can be homogenized in 50 µl of phosphate buffer and used to inoculate a single leaf of a tobacco plant. If virus is present in root cultures, within two to three days characteristic lesions will appear on infected leaves. This means that root line contains recombinant virus that carries a polynucleotide encoding a Y. pestis antigen (a target gene). If no local lesions are formed, there is no virus, and the root line is rejected as negative. This method is highly time- and cost-efficient. After initially screening for the presence of virus, roots that contain virus may be subjected to secondary screening, e.g., by western blot or ELISA to select high expressers. Additional screens, e.g., screens for rapid growth, growth in particular media or under particular environmental conditions, etc., can be applied. These screening methods may, in general, be applied in the development of any of clonal root lines, clonal root cell lines, clonal plant cell lines, and/or clonal plants described herein.

0111As will be evident to one of ordinary skill in the art, a variety of modifications may be made to the description of methods for generating clonal root lines that contain a viral vector. For example, while it is generally desirable to introduce viral vector into an intact plant or portion thereof prior to introduction of Ri T-DNA genes, in certain embodiments, Ri-DNA is introduced prior to introducing viral vector. In addition, it is possible to contact intact plants with A. rhizogenes rather than harvesting leaf portions and then exposing them to bacterium.

0112Other methods of generating clonal root lines from single cells of a plant or portion thereof that harbor a viral vector can be used (i.e., methods not using A. rhizogenes or genetic material from the Ri plasmid). For example, treatment with certain plant hormones or combinations of plant hormones is known to result in generation of roots from plant tissue.

Clonal Cell Lines Derived from Clonal Root Lines

0113As described above, the disclosure provides methods for generating clonal root lines, wherein cells in root lines contain a viral vector. As is well known in the art, a variety of different cell lines can be generated from roots. For example, root cell lines can be generated from individual root cells obtained from a root using a variety of known methods. Such root cell lines may be obtained from various different root cell types within a root. In general, root material is harvested and dissociated (e.g., physically and/or enzymatically digested) to release individual root cells, which are then further cultured. Complete protoplast formation is generally not necessary. If desired, root cells can be plated at very dilute cell concentrations, so as to obtain root cell lines from single root cells. Root cell lines derived in this manner are clonal root cell lines containing viral vector. Such root cell lines therefore exhibit stable expression of a polynucleotide encoding a Y. pestis antigens. Clonal plant cell lines can be obtained in a similar manner from clonal roots, e.g., by culturing dissociated root cells in the presence o.f appropriate plant hormones. Screens and successive rounds of enrichment can be used to identify cell lines that express a polynucleotide encoding a Y. pestis antigen at high levels. However, if the clonal root line from which a cell line is derived already expresses at high levels, such additional screens may be unnecessary.

0114As in the case of clonal root lines, cells of a clonal root cell line are derived from a single ancestral cell that contains viral vector and will, therefore, also contain viral vector since it will be replicated and will be transmitted during cell division. Thus a high proportion (e.g. at least 50%, at least 75%, at least 80%, at least 90%, at least 95%), all (i.e., 100%), or substantially all (e.g., at least 98%) of cells will contain viral vector. It is noted that since viral vector is inherited by daughter cells within a clonal root cell line, movement of viral vector among cells is not necessary to maintain viral vector. Clonal root cell lines can be used for production of a polynucleotide encoding Y. pestis antigen as described below.

Clonal Plant Cell Lines

0115The present disclosure provides methods for generating a clonal plant cell line in which a plant viral vector is used to direct expression of a polynucleotide encoding a Y. pestis antigen in accordance with the invention. According to methods in accordance with the disclosure, one or more viral expression vector(s) including a polynucleotide encoding a Y. pestis antigen operably linked to a promoter is introduced into cells of a plant cell line that is maintained in cell culture. A number of plant cell lines from various plant types are known in the art, any of which can be used. Newly derived cell lines can be generated according to known methods for use in practicing the invention. A viral vector is introduced into cells of a plant cell line according to any of a number of methods. For example, protoplasts can be made and viral transcripts then electroporated into cells. Other methods of introducing a plant viral vector into cells of a plant cell line can be used.

0116A method for generating clonal plant cell lines and a viral vector suitable for introduction into plant cells (e.g., protoplasts) can be used as follows: Following introduction of viral vector, a plant cell line may be maintained in tissue culture. During this time viral vector may replicate, and polynucleotide(s) encoding a Y. pestis antigen(s) may be expressed. Clonal plant cell lines are derived from culture, e.g., by a process of successive enrichment. For example, samples may be removed from culture, optionally with dilution so that the concentration of cells is low, and plated in Petri dishes in individual droplets. Droplets are then maintained to allow cell division.

0117It will be appreciated that droplets may contain a variable number of cells, depending on initial density of the culture and amount of dilution. Cells can be diluted such that most droplets contain either 0 or 1 cell if it is desired to obtain clonal cell lines expressing a polynucleotide encoding a Y. pestis antigen after only a single round of enrichment. However, it can be more efficient to select a concentration such that multiple cells are present in each droplet and then screen droplets to identify those that contain expressing cells. In general, any appropriate screening procedure can be employed. For example, selection or detection of a detectable marker such as GFP can be used. Western blots or ELISA assays can be used. Individual droplets (100 µl) contain more than enough cells for performance of these assays. Multiple rounds of enrichment are performed to isolate successively higher expressing cell lines. Single clonal plant cell lines (i.e., populations derived from a single ancestral cell) can be generated by further limiting dilution using standard methods for single cell cloning. However, it is not necessary to isolate individual clonal lines. A population containing multiple clonal cell lines can be used for expression of a polynucleotide encoding one or more Y. pestis antigen(s).

0118In general, certain considerations described above for generation of clonal root lines apply to generation of clonal plant cell lines. For example, a diversity of viral vectors containing one or more polynucleotide(s) encoding a Y. pestis antigen(s) in accordance with the invention can be used as combinations of multiple different vectors. Similar screening methods can be used. As in the case of clonal root lines and clonal root cell lines, cells of a clonal plant cell line are derived from a single ancestral cell that contains viral vector and will, therefore, also contain viral vector since it will be replicated and will be transmitted during cell division. Thus a high proportion (e.g. at least 50%, at least 75%, at least 80%, at least 90%, at least 95%), all (i.e., 100%), or substantially all (e.g., at least 98%) of cells will contain viral vector. It is noted that since viral vector is inherited by daughter cells within a clonal plant cell line, movement of viral vector among cells is not necessary to maintain viral vector. A clonal plant cell line can be used for production of a polypeptide encoding a Y. pestis antigen as described below.

Clonal Plants

0119Clonal plants can be generated from clonal roots, clonal root cell lines, and/or clonal plant cell lines produced according to various methods described above. Methods for generation of plants from roots, root cell lines, and plant cell lines such as clonal root lines, clonal root cell lines, and clonal plant cell lines described herein are well known in the art (see, e.g., <nplcit id="ncit0023" npl-type="b"><text>Peres et al., 2001, Plant Cell, Tissue, Organ Culture, 65:37</text></nplcit>; and standard reference works on plant molecular biology and biotechnology cited elsewhere herein). The disclosure therefore provides a method of generating a clonal plant comprising steps of (i) generating a clonal root line, clonal root cell line, or clonal plant cell line according to any of the methods described above; and (ii) generating a whole plant from a clonal root line, clonal root cell line, or clonal plant. Clonal plants may be propagated and grown according to standard methods.

0120As in the case of clonal root lines, clonal root cell lines, and clonal plant cell lines, cells of a clonal plant are derived from a single ancestral cell that contains viral vector and will, therefore, also contain viral vector since it will be replicated and will be transmitted during cell division. Thus a high proportion (e.g. at least 50%, at least 75%, at least 80%, at least 90%, at least 95%), all (i.e., 100%), or substantially all (e.g., at least 98%) of cells will contain viral vector. It is noted that since viral vector is inherited by daughter cells within a clonal plant, movement of viral vector is not necessary to maintain viral vector.

Sprouts and Sprouted Seedling Plant Expression Systems

0121Systems and reagents for generating a variety of sprouts and sprouted seedlings which are useful for production of Y. pestis antigen(s) have been described previously and are known in the art (see, for example, <patcit id="pcit0006" dnum="WO0443886A"><text>PCT Publication WO 04/43886</text></patcit>). The present disclosure further provides sprouted seedlings, which may be edible, as a biomass containing a Y. pestis antigen. In certain aspects, biomass is provided directly for consumption of antigen containing compositions. In some aspects, biomass is processed prior to consumption, for example, by homogenizing, crushing, drying, or extracting. In certain aspects, Y. pestis antigen is purified from biomass and formulated into a pharmaceutical composition.

0122Additionally provided are methods for producing Y. pestis antigen(s) in sprouted seedlings that can be consumed or harvested live (e.g., sprouts, sprouted seedlings of the Brassica genus). In certain aspects, the present disclosure involves growing a seed to an edible sprouted seedling in a contained, regulatable environment (e.g., indoors, in a container, etc.). A seed can be a genetically engineered seed that contains an expression cassette encoding a Y. pestis antigen, which expression is driven by an exogenously inducible promoter. A variety of exogenously inducible promoters can be used that are inducible, for example, by light, heat, phytohormones, nutrients, etc.

0123In related embodiments, the present disclosure provides methods of producing Y. pestis antigen(s) in sprouted seedlings by first generating a seed stock for a sprouted seedling by transforming plants with an expression cassette that encodes Y. pestis antigen using an Agrobacterium transformation system, wherein expression of a Y. pestis antigen is driven by an inducible promoter. Transgenic seeds can be obtained from a transformed plant, grown in a contained, regulatable environment, and induced to express a Y. pestis antigen.

0124In some embodiments methods are provided that involves infecting sprouted seedlings with a viral expression cassette encoding a Y. pestis antigen, expression of which may be driven by any of a viral promoter or an inducible promoter. Sprouted seedlings are grown for two to fourteen days in a contained, regulatable environment or at least until sufficient levels of Y. pestis antigen have been obtained for consumption or harvesting.

0125The present disclosure further provides systems for producing Y. pestis antigen(s) in sprouted seedlings that include a housing unit with climate control and a sprouted seedling containing an expression cassette that encodes one or more Y. pestis antigens, wherein expression is driven by a constitutive or inducible promoter. Systems can provide unique advantages over an outdoor environment or greenhouse, which cannot be controlled. Thus, the present disclosure enables a grower to precisely time induction of expression of Y. pestis antigen. It can greatly reduce time and cost of producing Y. pestis antigen(s).

0126In certain aspects, transiently transfected sprouts contain viral vector sequences encoding a Y. pestis antigen in accordance with the invention. Seedlings are grown for a time period so as to allow for production of viral nucleic acid in sprouts, followed by a period of growth wherein multiple copies of virus are produced, thereby resulting in production of Y. pestis antigen(s).

0127In certain aspects, genetically engineered seeds or embryos that contain a nucleic acid encoding Y. pestis antigen(s) are grown to sprouted seedling stage in a contained, regulatable environment. A contained, regulatable environment may be a housing unit or room in which seeds can be grown indoors. All environmental factors of a contained, regulatable environment may be controlled. Since sprouts do not require light to grow, and lighting can be expensive, genetically engineered seeds or embryos may be grown to sprouted seedling stage indoors in absence of light.

0128Other environmental factors that can be regulated in a contained, regulatable environment in accordance with the invention include temperature, humidity, water, nutrients, gas (e.g., O2 or CO2 content or air circulation), chemicals (small molecules such as sugars and sugar derivatives or hormones such as such as phytohormones gibberellic or absisic acid, etc.) and the like.

0129According to certain methods, expression of a nucleic acid encoding a Y. pestis antigen may be controlled by an exogenously inducible promoter. Exogenously inducible promoters are caused to increase or decrease expression of a nucleic acid in response to an external, rather than an internal stimulus. A number of environmental factors can act as inducers for expression of nucleic acids carried by expression cassettes of genetically engineered sprouts. A promoter may be a heat-inducible promoter, such as a heat-shock promoter. For example, using as heat-shock promoter, temperature of a contained environment may simply be raised to induce expression of a nucleic acid. Other promoters include light inducible promoters. Light-inducible promoters can be maintained as constitutive promoters if light in a contained regulatable environment is always on. Alternatively or additionally, expression of a nucleic acid can be turned on at a particular time during development by simply turning on a light. A promoter may be a chemically inducible promoter is used to induce expression of a nucleic acid. According to these embodiments, a chemical could simply be misted or sprayed onto seed, embryo, or seedling to induce expression of nucleic acid. Spraying and misting can be precisely controlled and directed onto target seed, embryo, or seedling to which it is intended. A contained environment is devoid of wind or air currents, which could disperse chemical away from intended target, so that the chemical stays on the target for which it was intended.

0130According to the present disclosure, time of expression is induced can be selected to maximize expression of a Y. pestis antigen in sprouted seedling by the time of harvest. Inducing expression in an embryo at a particular stage of growth, for example, inducing expression in an embryo at a particular number of days after germination, may result in maximum synthesis of a Y. pestis antigen at the time of harvest. To give but one example, in some situations, inducing expression from a promoter 4 days after germination may result in more protein synthesis than inducing expression from the promoter after 3 days or after 5 days. Those skilled in the art will appreciate that maximizing expression can be achieved by routine experimentation. In certain methods, sprouted seedlings are harvested at about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, or about 14 days after germination.

0131In cases where an expression vector has a constitutive promoter instead of an inducible promoter, sprouted seedling may be harvested at a certain time after transformation of sprouted seedling. For example, if a sprouted seedling were virally transformed at an early stage of development, for example, at embryo stage, sprouted seedlings may be harvested at a time when expression is at its maximum post-transformation, e.g., at about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, or about 14 days post-transformation. It could be that sprouts develop one, two, three or more months post-transformation, depending on germination of seed.

0132Generally, once expression of Y. pestis antigen(s) begins, seeds, embryos, or sprouted seedlings are allowed to grow until sufficient levels of Y. pestis antigen(s) are expressed. In certain aspects, sufficient levels are levels that would provide a therapeutic benefit to a patient if harvested biomass were eaten raw. Alternatively or additionally, sufficient levels are levels from which Y. pestis antigen can be concentrated or purified from biomass and formulated into a pharmaceutical composition that provides a therapeutic benefit to a patient upon administration. Typically, Y. pestis antigen is not a protein expressed in sprouted seedling in nature. At any rate, Y. pestis antigen is typically expressed at concentrations above that which would be present in a sprouted seedling in nature.

0133Once expression of Y. pestis antigen is induced, growth is allowed to continue until sprouted seedling stage, at which time sprouted seedlings are harvested. Sprouted seedlings can be harvested live. Harvesting live sprouted seedlings has several advantages including minimal effort and breakage. Sprouted seedlings in accordance with the invention may be grown hydroponically, making harvesting a simple matter of lifting a sprouted seedling from its hydroponic solution. No soil is required for growth of sprouted seedlings, but may be provided if deemed necessary or desirable by the skilled artisan. Because sprouts can be grown without soil, no cleansing of sprouted seedling material is required at the time of harvest. Being able to harvest a sprouted seedling directly from its hydroponic environment without washing or scrubbing minimizes breakage of harvested material. Breakage and wilting of plants induces apoptosis. During apoptosis, certain proteolytic enzymes become active, which can degrade pharmaceutical protein expressed in a sprouted seedling, resulting in decreased therapeutic activity of a protein. Apoptosis-induced proteolysis can significantly decrease yield of protein from mature plants. Using methods in accordance with the disclosure, apoptosis may be avoided when no harvesting takes place until the moment proteins are extracted from a plant.

0134For example, live sprouts may be ground, crushed, or blended to produce a slurry of sprouted seedling biomass, in a buffer containing protease inhibitors. Buffer may be maintained at about 4°C. In some aspects, sprouted seedling biomass is air-dried, spray dried, frozen, or freeze-dried. As in mature plants, some of these methods, such as air-drying, may result in a loss of activity of pharmaceutical protein. However, because sprouted seedlings are very small and have a large surface area to volume ratio, this is much less likely to occur. Those skilled in the art will appreciate that many techniques for harvesting biomass that minimize proteolysis of expressed protein are available and could be applied.

0135In some embodiments, sprouted seedlings are edible. In certain embodiments, sprouted seedlings expressing sufficient levels of Y. pestis antigens are consumed upon harvesting (e.g., immediately after harvest, within minimal period following harvest) so that absolutely no processing occurs before sprouted seedlings are consumed. In this way, any harvest-induced proteolytic breakdown of Y. pestis antigen before administration of Y. pestis antigen to a patient in need of treatment is minimized. For example, sprouted seedlings that are ready to be consumed can be delivered directly to a patient. Alternatively or additionally, genetically engineered seeds or embryos are delivered to a patient in need of treatment and grown to sprouted seedling stage by a patient. In one aspect, a supply of genetically engineered sprouted seedlings is provided to a patient, or to a doctor who will be treating patients, so that a continual stock of sprouted seedlings expressing certain desirable Y. pestis antigens may be cultivated. This may be particularly valuable for populations in developing countries, where expensive pharmaceuticals are not affordable or deliverable. The ease with which sprouted seedlings in accordance with the invention can be grown makes sprouted seedlings in accordance with the invention particularly desirable for such developing populations.

0136The regulatable nature of a contained environment imparts advantages to the present invention over growing plants in an outdoor environment. In general, growing genetically engineered sprouted seedlings that express pharmaceutical proteins in plants provides a pharmaceutical product faster (e.g., because plants are harvested younger) and with less effort, risk, and regulatory considerations than growing genetically engineered plants. A contained, regulatable environment used in the present invention reduces or eliminates risk of cross-pollinating plants in nature.

0137For example, a heat inducible promoter likely would not be used outdoors because outdoor temperature cannot be controlled. A promoter would be turned on any time that outdoor temperature rose above a certain level. Similarly, a promoter would be turned off every time outdoor temperature dropped. Such temperature shifts could occur in a single day, for example, turning expression on in the daytime and off at night. A heat inducible promoter, such as those described herein, would not even be practical for use in a greenhouse, which is susceptible to climatic shifts to almost the same degree as outdoors. Growth of genetically engineered plants in a greenhouse is quite costly. In contrast, in the present system, every variable can be controlled so that a maximum amount of expression can be achieved with every harvest.

0138In certain embodiments, sprouted seedlings are grown in trays that can be watered, sprayed, or misted at any time during development of sprouted seedling. For example, a tray may be fitted with one or more watering, spraying, misting, and draining apparatus that can deliver and/or remove water, nutrients, chemicals etc. at specific time and at precise quantities during development of a sprouted seedling. For example, seeds require sufficient moisture to keep them damp. Excess moisture drains through holes in trays into drains in the floor of a room. Typically, drainage water is treated as appropriate for removal of harmful chemicals before discharge back into the environment.

0139Another advantage of trays is that they can be contained within a very small space. Since no light is required for sprouted seedlings to grow, trays containing seeds, embryos, or sprouted seedlings may be tightly stacked vertically on top of one another, providing a large quantity of biomass per unit floor space in a housing facility constructed specifically for these purposes. In addition, stacks of trays can be arranged in horizontal rows within a housing unit. Once seedlings have grown to a stage appropriate for harvest (about two to fourteen days) individual seedling trays are moved into a processing facility, either manually or by automatic means, such as a conveyor belt.

0140Systems are unique in that they provide a sprouted seedling biomass, which is a source of a Y. pestis antigen(s). Whether consumed directly or processed into a form of a pharmaceutical composition, because sprouted seedlings are grown in a contained, regulatable environment, sprouted seedling biomass and/or pharmaceutical composition derived from biomass can be provided to a consumer at low cost. In addition, the fact that conditions for growth of sprouted seedlings can be controlled makes quality and purity of product consistent. A contained, regulatable environment obviates many safety regulations of the EPA that can prevent scientists from growing genetically engineered agricultural products out of doors.

Transformed Sprouts

0141A variety of methods can be used to transform plant cells and produce genetically engineered sprouted seedlings. Two available methods for transformation of plants that require that transgenic plant cell lines be generated in vitro, followed by regeneration of cell lines into whole plants include Agrobacterium tumefaciens mediated gene transfer and microprojectile bombardment or electroporation. Viral transformation is a more rapid and less costly method of transforming embryos and sprouted seedlings that can be harvested without an experimental or generational lag prior to obtaining desired product. For any of these techniques, the skilled artisan would appreciate how to adjust and optimize transformation protocols that have traditionally been used for plants, seeds, embryos, or spouted seedlings.

Agrobacterium Transformation Expression Cassettes

0142Agrobacterium is a representative genus of the gram-negative family Rhizobiaceae. This species is responsible for plant tumors such as crown gall and hairy root disease. In dedifferentiated plant tissue, which is characteristic of tumors, amino acid derivatives known as opines are produced by the Agrobacterium and catabolized by the plant. Bacterial genes responsible for expression of opines are a convenient source of control elements for chimeric expression cassettes. According to the present disclosure, Agrobacterium transformation system may be used to generate edible sprouted seedlings, which are merely harvested earlier than mature plants. Agrobacterium transformation methods can easily be applied to regenerate sprouted seedlings expressing Y. pestis antigens.

0143In general, transforming plants involves transformation of plant cells grown in tissue culture by co-cultivation with an Agrobacterium tumefaciens carrying a plant/bacterial vector. The vector contains a gene encoding a Y. pestis antigen. An Agrobacterium transfers vector to plant host cell and is then eliminated using antibiotic treatment. Transformed plant cells expressing Y. pestis antigen are selected, differentiated, and finally regenerated into complete plantlets (<nplcit id="ncit0024" npl-type="s"><text>Hellens et al., 2000, Plant Mol. Biol., 42:819</text></nplcit>; <nplcit id="ncit0025" npl-type="s"><text>Pilon-Smits et al., 1999, Plant Physiolog., 119:123</text></nplcit>; <nplcit id="ncit0026" npl-type="s"><text>Barfield et al., 1991, Plant Cell Reports, 10:308</text></nplcit>; and <nplcit id="ncit0027" npl-type="s"><text>Riva et al., 1998, J. Biotech., 1(3</text></nplcit>)).

0144Expression vectors for use in the present invention include a gene (or expression cassette) encoding a Y. pestis antigen designed for operation in plants, with companion sequences upstream and downstream of an expression cassette. Companion sequences are generally of plasmid or viral origin and provide necessary characteristics to a vector to transfer DNA from bacteria to the desired plant host.

0145A basic bacterial/plant vector construct may desirably provide a broad host range prokaryote replication origin, a prokaryote selectable marker. Suitable prokaryotic selectable markers include resistance toward antibiotics such as ampicillin or tetracycline. Other DNA sequences encoding additional functions that are well known in the art may be present in a vector.

0146Agrobacterium T-DNA sequences are required for Agrobacterium mediated transfer of DNA to a plant chromosome. Tumor-inducing genes of T-DNA are typically removed and replaced with sequences encoding a Y. pestis antigen. T-DNA border sequences are retained because they initiate integration of T-DNA region into a plant genome. If expression of Y. pestis antigen is not readily amenable to detection, a bacterial/plant vector construct may include a selectable marker gene suitable for determining if a plant cell has been transformed, e.g., nptII kanamycin resistance gene. On the same or different bacterial/plant vector (Ti plasmid) are Ti sequences. Ti sequences include virulence genes, which encode a set of proteins responsible for excision, transfer and integration of T-DNA into a plant genome (<nplcit id="ncit0028" npl-type="s"><text>Schell, 1987, Science, 237:1176</text></nplcit>). Other sequences suitable for permitting integration of heterologous sequence into a plant genome may include transposon sequences, and the like, for homologous recombination.

0147Certain constructs will include an expression cassette encoding an antigen protein. One, two, or more expression cassettes may be used in a given transformation. A recombinant expression cassette contains, in addition to a Y. pestis antigen encoding sequence, at least the following elements: a promoter region, plant 5' untranslated sequences, initiation codon (depending upon whether or not an expressed gene has its own), and transcription and translation termination sequences. In addition, transcription and translation terminators may be included in expression cassettes or chimeric genes in accordance with the invention. Signal secretion sequences that allow processing and translocation of a protein, as appropriate, may be included in an expression cassette. A variety of promoters, signal sequences, and transcription and translation terminators are described, for example, in <nplcit id="ncit0029" npl-type="s"><text>Lawton et al. (1987, Plant Mol. Biol., 9:315</text></nplcit>) and in <patcit id="pcit0007" dnum="US5888789A"><text>U.S. Patent 5,888,789</text></patcit>). In addition, structural genes for antibiotic resistance are commonly utilized as a selection factor (<nplcit id="ncit0030" npl-type="s"><text>Fraley et al. 1983, Proc. Natl. Acad. Ski., USA, 80:4803</text></nplcit>). Unique restriction enzyme sites at the 5' and 3' ends of a cassette allow for easy insertion into a pre-existing vector. Other binary vector systems for Agrobacterium-mediated transformation, carrying at least one T-DNA border sequence are described (<patcit id="pcit0008" dnum="EP9907414W"><text>PCT/EP99/07414</text></patcit>).

Regeneration

0148Seeds of transformed plants may be harvested, dried, cleaned, and tested for viability and for presence and expression of a desired gene product. Once this has been determined, seed stock is typically stored under appropriate conditions of temperature, humidity, sanitation, and security to be used when necessary. Whole plants may then be regenerated from cultured protoplasts, e.g., as described in <nplcit id="ncit0031" npl-type="b"><text>Evans et al. (Handbook of Plant Cell Cultures, Vol. 1, MacMillan Publishing Co., New York, NY, 1983</text></nplcit>); and in <nplcit id="ncit0032" npl-type="b"><text>Vasil (ed., Cell Culture and Somatic Cell Genetics of Plants, Acad. Press, Orlando, FL, Vol. I, 1984</text></nplcit>, and <nplcit id="ncit0033" npl-type="b"><text>Vol. III, 1986</text></nplcit>). In certain aspects, plants are regenerated only to sprouted seedling stage. In some aspects, whole plants are regenerated to produce seed stocks and sprouted seedlings are generated from seeds of a seed stock.

0149All plants from which protoplasts can be isolated and cultured to give whole, regenerated plants can be transformed so that whole plants are recovered that contain a transferred gene. It is known that practically all plants can be regenerated from cultured cells or tissues, including, but not limited to, all major species of plants that produce edible sprouts. Some suitable plants include alfalfa, mung bean, radish, wheat, mustard, spinach, carrot, beet, onion, garlic, celery, rhubarb, a leafy plant such as cabbage or lettuce, watercress or cress, herbs such as parsley, mint, or clovers, cauliflower, broccoli, soybean, lentils, edible flowers such as sunflower, etc.

0150Means for regeneration vary from one species of plants to the next. However, those skilled in the art will appreciate that generally a suspension of transformed protoplants containing copies of a heterologous gene is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively or additionally, embryo formation can be induced from a protoplast suspension. These embryos germinate as natural embryos to form plants. Steeping seed in water or spraying seed with water to increase the moisture content of a seed to between 35% - 45% initiates germination. For germination to proceed, seeds are typically maintained in air saturated with water under controlled temperature and airflow conditions. Culture media generally contains various amino acids and hormones, such as auxin and cytokinins. In some embodiments, it is advantageous to add glutamic acid and proline to the medium, especially for such species as alfalfa. Shoots and roots normally develop simultaneously. Efficient regeneration typically depends on the medium, the genotype, and the history of the culture. If these three variables are controlled, then regeneration can be fully reproducible and repeatable.

0151Mature plants, grown from transformed plant cells, are selfed and non-segregating, homozygous transgenic plants are identified. An inbred plant produces seeds containing antigen-encoding sequences. Such seeds can be germinated and grown to sprouted seedling stage to produce Y. pestis antigen(s).

0152In related embodiments, seeds may be formed into seed products and sold with instructions on how to grow seedlings to an appropriate sprouted seedling stage for administration or harvesting into a pharmaceutical composition. In some related embodiments, hybrids or novel varieties embodying desired traits may be developed from inbred plants.

Direct Integration

0153Direct integration of DNA fragments into the genome of plant cells by microprojectile bombardment or electroporation may be used in the present invention (see, e.g., <nplcit id="ncit0034" npl-type="s"><text>Kikkert, et al., 1999, Plant: J. Tiss. Cult. Assoc., 35:43</text></nplcit>; and <nplcit id="ncit0035" npl-type="s"><text>Bates, 1994, Mol. Biotech., 2:135</text></nplcit>). More particularly, vectors that express Y. pestis antigen(s) can be introduced into plant cells by a variety of techniques. As described above, vectors may include selectable markers for use in plant cells. Vectors may include sequences that allow their selection and propagation in a secondary host, such as sequences containing an origin of replication and selectable marker. Typically, secondary hosts include bacteria and yeast. In some embodiments, a secondary host is bacteria (e.g., Escherichia coli, the origin of replication is a colE1-type origin of replication) and a selectable marker is a gene encoding ampicillin resistance. Such sequences are well known in the art and are commercially available (e.g., Clontech, Palo Alto, CA or Stratagene, La Jolla, CA).

0154Vectors may be modified to intermediate plant transformation plasmids that contain a region of homology to an Agrobacterium tumefaciens vector, a T-DNA border region from Agrobacterium tumefaciens, and antigen encoding nucleic acids or expression cassettes described above. Further vectors may include a disarmed plant tumor inducing plasmid of Agrobacterium tumefaciens.

0155According to this embodiment, direct transformation of vectors invention may involve microinjecting vectors directly into plant cells by use of micropipettes to mechanically transfer recombinant DNA (see, e.g., <nplcit id="ncit0036" npl-type="s"><text>Crossway, 1985, Mol. Gen. Genet., 202:179</text></nplcit>). Genetic material may be transferred into a plant cell using polyethylene glycols (see, e.g., <nplcit id="ncit0037" npl-type="s"><text>Krens et al., 1982, Nature 296:72</text></nplcit>). Another method of introducing nucleic acids into plants via high velocity ballistic penetration by small particles with a nucleic acid either within the matrix of small beads or particles, or on the surface (see, e.g., <nplcit id="ncit0038" npl-type="s"><text>Klein et al., 1987, Nature 327:70</text></nplcit>; and <nplcit id="ncit0039" npl-type="s"><text>Knudsen et al., Planta, 185:330</text></nplcit>). Yet another method of introduction is fusion of protoplasts with other entities, either minicells, cells, lysosomes, or other fusible lipid-surfaced bodies (see, e.g., <nplcit id="ncit0040" npl-type="s"><text>Fraley et al., 1982, Proc. Natl. Acad. Sci., USA, 79:1859</text></nplcit>. Vectors in accordance with the invention may be introduced into plant cells by electroporation (see, e.g., <nplcit id="ncit0041" npl-type="s"><text>Fromm et al. 1985, Proc. Natl. Acad. Sci., USA, 82:5824</text></nplcit>). According to this technique, plant protoplasts are electroporated in the presence of plasmids containing a gene construct. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing introduction of plasmids. Electroporated plant protoplasts reform the cell wall divide and form plant callus, which can be regenerated to form sprouted seedlings in accordance with the invention. Those skilled in the art will appreciate how to utilize these methods to transform plants cells that can be used to generate edible sprouted seedlings.

Viral Transformation

0156Similar to conventional expression systems, plant viral vectors can be used to produce full-length proteins, including full length antigen. Plant virus vectors may be used to infect and produce antigen(s) in seeds, embryos, sprouted seedlings, etc. Viral system that can be used to express everything from short peptides to large complex proteins. Specifically, using tobamoviral vectors is described, for example, by <nplcit id="ncit0042" npl-type="s"><text>McCormick et al. (1999, Proc. Natl. Acad. Sci., USA, 96:703</text></nplcit>; <nplcit id="ncit0043" npl-type="s"><text>Kumagai et al. 2000, Gene, 245:169</text></nplcit>; and <nplcit id="ncit0044" npl-type="s"><text>Verch et al., 1998, J. Immunol. Methods, 220:69</text></nplcit>). Thus, plant viral vectors have a demonstrated ability to express short peptides as well as large complex proteins.

0157In certain embodiments, transgenic sprouts, which express Y. pestis antigen, are generated utilizing a host/virus system. Transgenic sprouts produced by viral infection provide a source of transgenic protein that has already been demonstrated to be safe. For example, sprouts are free of contamination with animal pathogens. Unlike, for example, tobacco, proteins from an edible sprout could at least in theory be used in oral applications without purification, thus significantly reducing costs. In addition, a virus/sprout system offers a much simpler, less expensive route for scale-up and manufacturing, since transgenes are introduced into virus, which can be grown up to a commercial scale within a few days. In contrast, transgenic plants can require up to 5 - 7 years before sufficient seed or plant material is available for large-scale trials or commercialization.

0158Plant RNA viruses have certain advantages, which make them attractive as vectors for foreign protein expression. Molecular biology and pathology of a number of plant RNA viruses are well characterized and there is considerable knowledge of virus biology, genetics, and regulatory sequences. Most plant RNA viruses have small genomes and infectious cDNA clones are available to facilitate genetic manipulation. Once infectious virus material enters a susceptible host cell, it replicates to high levels and spreads rapidly throughout an entire sprouted seedling (one to fourteen days post-inoculation, e.g., about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, or about 14 days post-inoculation). Virus particles are easily and economically recovered from infected sprouted seedling tissue. Viruses have a wide host range, enabling use of a single construct for infection of several susceptible species. These characteristics are readily transferable to sprouts.

0159Foreign sequences can be expressed from plant RNA viruses, typically by replacing one of the viral genes with desired sequence, by inserting foreign sequences into a virus genome at an appropriate position, or by fusing foreign peptides to structural proteins of a virus. Moreover, any of these approaches can be combined to express foreign sequences by trans-complementation of vital functions of a virus. A number of different strategies exist as tools to express foreign sequences in virus-infected plants using tobacco mosaic virus (TMV), alfalfa mosaic virus (A1MV), and chimeras thereof.

0160The genome of A1MV is a representative of the Bromoviridae family of viruses and consists of three genomic RNAs (RNAs1-3) and subgenomic RNA (RNA4). Genomic RNA and 2 encode virus replicase proteins P1 and P2, respectively. Genomic RNA3 encodes cell-to-cell movement protein P3 and coat protein (CP). CP is translated from subgenomic RNA4, which is synthesized from genomic RNA3, and is required to start infection. Studies have demonstrated involvement of CP in multiple functions, including genome activation, replication, RNA stability, symptom formation, and RNA encapsidation (see e.g., <nplcit id="ncit0045" npl-type="s"><text>Bol et al., 1971, Virology, 46:73</text></nplcit>; <nplcit id="ncit0046" npl-type="s"><text>Van Der Vossen et al., 1994, Virology 202:891</text></nplcit>; <nplcit id="ncit0047" npl-type="s"><text>Yusibov et al., Virology, 208:405</text></nplcit>; <nplcit id="ncit0048" npl-type="s"><text>Yusibov et al., 1998, Virology, 242:1</text></nplcit>; <nplcit id="ncit0049" npl-type="s"><text>Bol et al., (Review, 100 refs.), 1999, J. Gen. Virol., 80:1089</text></nplcit>; <nplcit id="ncit0050" npl-type="s"><text>De Graaff, 1995, Virology, 208:583</text></nplcit>; <nplcit id="ncit0051" npl-type="s"><text>Jaspars et al., 1974, Adv. Virus Res., 19:37</text></nplcit>; <nplcit id="ncit0052" npl-type="s"><text>Loesch-Fries, 1985, Virology, 146:177</text></nplcit>; <nplcit id="ncit0053" npl-type="s"><text>Neeleman et al., 1991, Virology, 181:687</text></nplcit>; <nplcit id="ncit0054" npl-type="s"><text>Neeleman et al., 1993, Virology, 196: 883</text></nplcit>; <nplcit id="ncit0055" npl-type="s"><text>Van Der Kuyl et al., 1991, Virology, 183:731</text></nplcit>; and <nplcit id="ncit0056" npl-type="s"><text>Van Der Kuyl et al., 1991, Virology, 185:496</text></nplcit>).

0161Encapsidation of viral particles is typically required for long distance movement of virus from inoculated to un-inoculated parts of seed, embryo, or sprouted seedling and for systemic infection. Inoculation can occur at any stage of plant development. In embryos and sprouts, spread of inoculated virus should be very rapid. Virions of A1MV are encapsidated by a unique CP (24 kD), forming more than one type of particle. The size (30 to 60 nm in length and 18 nm in diameter) and shape (spherical, ellipsoidal, or bacilliform) of a particle depends on the size of an encapsidated RNA. Upon assembly, the N-terminus of A1MV CP is thought to be located on the surface of virus particles and does not appear to interfere with virus assembly (<nplcit id="ncit0057" npl-type="s"><text>Bol et al., 1971, Virology, 6:73</text></nplcit>). Additionally, ALMV CP with an additional 38-amino acid peptide at its N-terminus forms particles in vitro and retains biological activity (<nplcit id="ncit0058" npl-type="s"><text>Yusibov et al., 1995, J. Gen. Virol., 77:567</text></nplcit>).

0162A1MV has a wide host range, which includes a number of agriculturally valuable crop plants, including plant seeds, embryos, and sprouts. Together, these characteristics make ALMV CP an excellent candidate as a carrier molecule and A1MV an attractive candidate vector for expression of foreign sequences in a plant at the sprout stage of development. Moreover, upon expression from a heterologous vector such as TMV, A1MV CP encapsidates TMV genome without interfering with virus infectivity (<nplcit id="ncit0059" npl-type="s"><text>Yusibov et al., 1997, Proc. Natl. Acad. Sci., USA, 94:5784</text></nplcit>). This allows use of TMV as a carrier virus for A1MV CP fused to foreign sequences.

0163TMV, the prototype of tobamoviruses, has a genome consisting of a single plus-sense RNA encapsidated with a 17.0 kD CP, which results in rod-shaped particles (about 300 nm in length). CP is the only structural protein of TMV and is required for encapsidation and long distance movement of virus in an infected host (<nplcit id="ncit0060" npl-type="s"><text>Saito et al., 1990, Virology 176:329</text></nplcit>). 183 kD and 126 kD proteins are translated from genomic RNA and are required for virus replication (<nplcit id="ncit0061" npl-type="s"><text>Ishikawa et al., 1986, Nucleic Acids Res., 14: 8291</text></nplcit>). 30 kD protein is the cell-to-cell movement protein of virus (<nplcit id="ncit0062" npl-type="s"><text>Meshi et al., 1987, EMBO J., 6:2557</text></nplcit>). Movement and coat proteins are translated from subgenomic mRNAs (<nplcit id="ncit0063" npl-type="s"><text>Hunter et al., 1976, Nature, 260:759</text></nplcit>; <nplcit id="ncit0064" npl-type="s"><text>Bruening et al., 1976, Virology, 71:498</text></nplcit>; and <nplcit id="ncit0065" npl-type="s"><text>Beachy et al., 1976, Virology, 73:498</text></nplcit>).

0164Other methods of transforming plant tissues include transforming a flower of a plant. Transformation of Arabidopsis thaliana can be achieved by dipping plant flowers into a solution of Agrobacterium tumefaciens (<nplcit id="ncit0066" npl-type="s"><text>Curtis et al., 2001, Transgenic Res., 10:363</text></nplcit>; and <nplcit id="ncit0067" npl-type="s"><text>Qing et al., 2000, Molecular Breeding: New Strategies in Plant Improvement 1:67</text></nplcit>). Transformed plants are formed in a population of seeds generated by "dipped" plants. At a specific point during flower development, a pore exists in the ovary wall through which Agrobacterium tumefaciens gains access to the interior of an ovary. Once inside the ovary, Agrobacterium tumefaciens proliferates and transforms individual ovules (<nplcit id="ncit0068" npl-type="s"><text>Desfeux et al., 2000, Plant Physiology, 123:895</text></nplcit>). Transformed ovules follow the typical pathway of seed formation within an ovary.

Agrobacterium-Mediated Transient Expression

0165As indicated herein, in many embodiments, systems for rapid (e.g., transient) expression of proteins or polypeptides in plants are desirable. Among other things, the present invention provides a powerful system for achieving such rapid expression in plants that utilizes an agrobacterial construct to deliver a viral expression system encoding a protein or polypeptide of interest. In some embodiments, any of the Y. pestis antigens described herein can be expressed utilizing launch vector technology, e.g., as described below. In some embodiments, launch vector constructs can also be utilized in the context of thermostable proteins, as described in more detail in the section entitled "Y. pestis Poplypeptide Fusions with Thermostable Proteins."

0166In some embodiments a "launch vector" is prepared that contains agrobacterial sequences including replication sequences and also contains plant viral sequences (including self-replication sequences) that carry a gene encoding a protein or polypeptide of interest. A launch vector is introduced into plant tissue, typically by agroinfiltration, which allows substantially systemic delivery. For transient transformation, non-integrated T-DNA copies of the launch vector remain transiently present in the nucleus and are transcribed leading to expression of the carrying genes (<nplcit id="ncit0069" npl-type="s"><text>Kapila et al., 1997, Plant Science, 122:101-108</text></nplcit>). Agrobacterium-mediated transient expression, differently from viral vectors, cannot lead to systemic spreading of expression of a gene of interest. One advantage of this system is the possibility to clone genes larger than 2 kb to generate constructs that would be impossible to obtain with viral vectors (<nplcit id="ncit0070" npl-type="s"><text>Voinnet et al., 2003, Plant J., 33:949-56</text></nplcit>). Furthermore, using such technique, it is possible to transform a plant with more than one transgene, such that multimeric proteins (e.g., antibodies subunits of complexed proteins) can be expressed and assembled. Furthermore, the possibility of co-expression of multiple transgenes by means of co-infiltration with different Agrobacterium can be taken advantage of, either by separate infiltration or using mixed cultures.

0167In certain embodiments, a launch vector includes sequences that allow for selection (or at least detection) in Agrobacteria and for selection/detection in infiltrated tissues. Furthermore, a launch vector typically includes sequences that are transcribed in a plant to yield viral RNA production, followed by generation of viral proteins. Furthermore, production of viral proteins and viral RNA yields rapid production of multiple copies of RNA encoding a pharmaceutically active protein of interest. Such production results in rapid protein production of a target of interest in a relatively short period of time. Thus, a highly efficient system for protein production can be generated.

0168Agroinfiltration utilizing viral expression vectors can be used to produce limited quantity of protein of interest in order to verify expression levels before deciding if it is worth generating transgenic plants. Alternatively or additionally, agroinfiltration utilizing viral expression vectors is useful for rapid generation of plants capable of producing huge amounts of protein as a primary production platform. Thus, this transient expression system can be used on industrial scale.

0169Further provided are any of a variety of different Agrobacterial plasmids, binary plasmids, or derivatives thereof such as pBIV, pBI1221, pGreen, etc., which can be used in these and other aspects of the invention. Numerous suitable vectors are known in the art and can be directed and/or modified according to methods known in the art, or those described herein so as to utilize in methods described provided herein.

0170One particular exemplary launch vector is pBID4. This vector contains the 35S promoter of cauliflower mosaic virus (a DNA plant virus) that drives initial transcription of the recombinant viral genome following introduction into plants, and the nos terminator, the transcriptional terminator of Agrobacterium nopaline synthase. The vector further contains sequences of the tobacco mosaic virus genome including genes for virus replication (126/183K) and cell-t-cell movement (MP). The vector further contains a gene encoding a polypeptide of interest, inserted into a unique cloning site within the tobacco mosaic virus genome sequences and under the transcriptional control of the coat protein subgenomic mRNA promoter. Because this "target gene" (i.e., gene encoding a protein or polypeptide of interest) replaces coding sequences for the TMV coat protein, the resultant viral vector is naked self-replicating RNA that is less subject to recombination than CP-containing vectors, and that cannot effectively spread and survive in the environment. Left and right border sequences (LB and RB) delimit the region of the launch vector that is transferred into plant cells following infiltration of plants with recombinant Agrobacterium carrying the vector. Upon introduction of agrobacteria carrying this vector into plant tissue (typically by agroinfiltration but alternatively by injection or other means), multiple single-stranded DNA (ssDNA) copies of sequence between LB and RB are generated and released in a matter of minutes. These introduced sequences are then amplified by viral replication. Translation of the target gene results in accumulation of large amounts of target protein or polypeptide in a short period of time.

0171In some embodiments, Agrobacterium-mediated transient expression produces up to about 5 g or more of target protein per kg of plant tissue. For example, in some embodiments, up to about 4, about 3, about 2, about 1, or about 0.5 g of target protein is produced per kg of plant tissue. In some embodiments, at least about 20 - about 500 mg, or about 50 - about 500 of target protein, or about 50 - about 200, or about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, about 1000, about 1500, about 1750, about 2000, about 2500, about 3000 mg, or more of protein per kg of plant tissue is produced.

0172In some embodiments, these expression levels are achieved within about 6, about 5, about 4, about 3, or about 2 weeks from infiltration. In some embodiments, these expression levels are achieved within about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2 days, or even 1 day, from introduction of an expression construct. Thus, the time from introduction (e.g., infiltration) to harvest is typically less than about 2 weeks, less than about 10 days, less than about 1 week, or less than a few days. Furthermore, the invention allows production of protein within about 8 weeks or less from the selection of amino acid sequence (even including time for "preliminary" expression studies). Also, each batch of protein can typically be produced within about 8 weeks, about 6, weeks, about 5 weeks, or less. Those of ordinary skill in the art will appreciate that these numbers may vary somewhat depending on the type of plant used. Most sprouts, including peas, will fall within the numbers given. Nicotiana benthamiana, however, may be grown longer, particularly prior to infiltration, as they are slower growing (from a much smaller seed). Other expected adjustments will be clear to those of ordinary skill in the art based on biology of the particular plants utilized. In some embodiments, certain pea varieties including for example, marrowfat pea, bill jump pea, yellow trapper pea, speckled pea, and green pea are particularly useful.

0173The inventors have also found that various Nicotiana plants are particularly useful in the practice of some aspects of the invention, including in particular Nicotiana benthamiana. In general, Nicotiana benthamiana plants are grown for a time sufficient to allow development of an appropriate amount of biomass prior to infiltration (i.e., to delivery of agrobacteria containing launch vector). Typically, plants are grown for a period of more than about 3 weeks, more typically more than about 4 weeks, or between about 5 - about 6 weeks to accumulate biomass prior to infiltration.

0174The present inventors have further surprisingly found that, although both TMV and A1MV sequences can prove effective in such launch vector constructs, in some embodiments, A1MV sequences are particularly efficient at ensuring high level production of delivered protein or polypeptides.

0175Thus, in certain particular embodiments, proteins or polypeptides of interest are produced in plants (e.g., Nicotiana benthamiana) from a launch vector that directs production of AlMV sequences carrying a gene of interest.

Yersinia pestis

Poplypeptide Fusions with Thermostable Proteins

0176In certain aspects, provided are Y. pestis antigen(s) comprising fusion polypeptides which comprise a Y. pestis protein (or a fragment or variant thereof) operably linked to a thermostable protein (e.g., LicB, LicKM, etc., and described in further detail below). Fusion polypeptides can be produced in any available expression system known in the art (including, but not limited to, launch vector technology). In certain embodiments, fusion proteins are produced in a plant or portion thereof (e.g., plant, plant cell, root, sprout, etc.).

0177Enzymes or other proteins which are not found naturally in humans or animal cells are particularly appropriate for use in fusion polypeptides in accordance with the invention. Thermostable proteins that, when fused, confer thermostability to a fusion product are useful. Thermostability allows produced protein to maintain conformation, and maintain produced protein at room temperature. This feature facilitates easy, time efficient and cost effective recovery of a fusion polypeptide. A representative family of thermostable enzymes useful in accordance with the invention is the glucanohydrolase family. These enzymes specifically cleave 1,4-β glucosidic bonds that are adjacent to 1,3-p linkages in mixed linked polysaccharides (<nplcit id="ncit0071" npl-type="s"><text>Hahn et al., 1994 Proc. Natl. Acad. Sci., USA, 91:10417</text></nplcit>). Such enzymes are found in cereals, such as oat and barley, and are also found in a number of fungal and bacterial species, including C. thermocellum (Goldenkova et al., 2002, Mol. Biol. 36:698). Thus, desirable thermostable proteins for use in fusion polypeptides in accordance with the invention include glycosidase enzymes. Exemplary thermostable glycosidase proteins include those represented by GenBank accession numbers selected from those set forth in Table 1. Exemplary thermostable enzymes of use in fusion proteins in accordance with the invention include Clostridium thermocellum P29716, Brevibacillus brevis P37073, and Rhodthermus marinus P45798, each of which are incorporated herein by reference to their GenBank accession numbers. Representative fusion proteins illustrated in the Examples utilize modified thermostable enzyme isolated from Clostridium thermocellum, however, any thermostable protein may be similarly utilized in accordance with the present invention. <tables id="tabl0001" num="0001"><table frame="all"><title>Table 1: Thermostable Glycosidase Proteins</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="40mm" /><colspec colnum="2" colname="col2" colwidth="88mm" /><tbody><row><entry>P29716</entry><entry>(Beta-glucanase Clostridium thermocellum)</entry></row><row><entry>P37073</entry><entry>Beta-lucanase Brevibacillus brevis)</entry></row><row><entry>1MVE_A</entry><entry>(Beta-glucanase Fibrobacter succinogenes)</entry></row><row><entry>P07883</entry><entry>(Extracellular agarase Streptomyces coelicolor)</entry></row><row><entry>P23903</entry><entry>(Glucan endo-13-beta-glucosidase A1 Bacillus circulans)</entry></row><row><entry>P27051</entry><entry>(Beta-lucanase Bacillus licheniformis)</entry></row><row><entry>P45797</entry><entry>(Beta-glucanase Paenibacillus polymyxa (Bacillus poymyxa))</entry></row><row><entry>P37073</entry><entry>(Beta-glucanase Brevibacillus brevis)</entry></row><row><entry>P45798</entry><entry>Beta-lucanase Rhodothermus marinus</entry></row><row><entry>P38645</entry><entry>(Beta-glucosidase Thermobispora bispora)</entry></row><row><entry>P40942</entry><entry>(Celloxylanase Clostridium stercorarium)</entry></row><row><entry>P14002</entry><entry>Beta-lucosidase Clostridium thermocellum)</entry></row><row><entry>033830</entry><entry>Alha-lucosidase Thermotoga maritima)</entry></row><row><entry>043097</entry><entry>(Xylanase Thermomyces lanuginosus)</entry></row><row><entry>P54583</entry><entry>(Endo-glucanase E1 Acidothermus cellulolyticus)</entry></row><row><entry>P14288</entry><entry>(Beta-galactosidase Sulfolobus acidocaldarius)</entry></row><row><entry>052629</entry><entry>(Beta-galactosidase Pyrococcus woesei)</entry></row><row><entry>P29094</entry><entry>(Oligo-16-glucosidase Geobacillus thermoglucosidasius)</entry></row><row><entry>P49067</entry><entry>(Alpha-amylase Prococcus furiosus)</entry></row><row><entry>JC7532</entry><entry>(Cellulase Bacillus species)</entry></row><row><entry>Q60037</entry><entry>(Xylanase A Thermotoga maritima)</entry></row><row><entry>P33558</entry><entry>(Xylanase A Clostridium stercorarium)</entry></row><row><entry>P05117</entry><entry>(Polygalacturonase-2 precursor Solanum lycopersicum)</entry></row><row><entry>P04954</entry><entry>(Cellulase D Clostridium thermocellum)</entry></row><row><entry>Q4J929</entry><entry>(N-glycosylase Sulfolobus acidocaldarius)</entry></row><row><entry>033833</entry><entry>(Beta-fructosidase Thermotoga maritima)</entry></row><row><entry>P49425</entry><entry>Endo-14-beta-mannosidase Rhodothermus marinus)</entry></row><row><entry>P06279</entry><entry>(Alpha-amylase Geobacillus stearothermophilus)</entry></row><row><entry>P45702 P45703 P40943</entry><entry>(Xylanase Geobacillus stearothermophilus)</entry></row><row><entry>P09961</entry><entry>(Alpha-amylase 1 Dictyoglomus thermophilum)</entry></row><row><entry>Q60042</entry><entry>(Xylanase A Thermotoga neapolitana)</entry></row><row><entry>AAN05438 AAN05439</entry><entry>Beta-glycosidase Thermus thermophilus)</entry></row><row><entry>AAN05437</entry><entry>(Sugar permease Thermus thermophilus)</entry></row><row><entry>AAN05440</entry><entry>Beta-glycosidase Thermus filiformis)</entry></row><row><entry>AAD43138</entry><entry>(Beta-glycosidase Thermosphaera aggregans)</entry></row></tbody></tgroup></table></tables>

0178When designing fusion proteins and polypeptides it is desirable, of course, to preserve immunogenicity of an antigen. Still further, it is desirable in certain aspects to provide constructs which provide thermostability of a fusion protein. This feature facilitates easy, time efficient and cost effective recovery of a target antigen. In certain aspects, antigen fusion partners may be selected which provide additional advantages, including enhancement of immunogenicity, potential to incorporate multiple vaccine determinants, yet lack prior immunogenic exposure to vaccination subjects. Further beneficial qualities of fusion peptides of interest include proteins which provide ease of manipulation for incorporation of one or more antigens, as well as proteins which have potential to confer ease of production, purification, and/or formulation for vaccine preparations. One of ordinary skill in the art will appreciate that three dimensional presentation can affect each of these beneficial characteristics. Preservation of immunity or preferential qualities therefore may affect, for example, choice of fusion partner and/or choice of fusion location (e.g., N-terminus, C-terminus, internal, combinations thereof). Alternatively or additionally, preferences may affects length of segment selected for fusion, whether it be length of antigen, or length of fusion partner selected.

0179The present inventors have demonstrated successful fusion of a variety of antigens with a thermostable protein. For example, the present inventors have used the thermostable carrier molecule LicB, also referred to as lichenase, for production of fusion proteins. LicB is 1,3-1,4-β glucanase (LicB) from Clostridium thermocellum (GenBank accession: X63355 [gi:40697]). LicB belongs to a family of globular proteins. Based on the three dimensional structure of LicB, its N- and C-termini are situated close to each other on the surface, in close proximity to the active domain. LicB also has a loop structure exposed on the surface that is located far from the active domain. We have generated constructs such that the loop structure and N- and C-termini of protein can be used as insertion sites for Y. pestis antigen polypeptides. Y. pestis antigen polypeptides can be expressed as N- or C-terminal fusions or as inserts into the surface loop. Importantly, LicB maintains its enzymatic activity at low pH and at high temperature (up to about 75°C). Thus, use of LicB as a carrier molecule contributes advantages, including likely enhancement of target specific immunogenicity, potential to incorporate multiple vaccine determinants, and straightforward formulation of vaccines that may be delivered nasally, orally or parenterally. Furthermore, production of LicB fusions in plants should reduce the risk of contamination with animal or human pathogens. See examples provided herein.

0180Fusion proteins comprising Y. pestis antigen may be produced in any of a variety of expression systems, including both in vitro and in vivo systems. One skilled in the art will readily appreciate that optimization of nucleic acid sequences for a particular expression system is often desirable. For example, in the Exemplification provided herein, optimized sequence for expression of Y. pestis antigen-LicKM fusions in plants is provided (see Examples 1 and 2). Thus, any relevant nucleic acid encoding Y. pestis antigen(s) fusion protein(s) and fragments thereof is intended to be encompassed within nucleic acid constructs.

0181For production in plant systems, transgenic plants expressing Y. pestis antigen(s) (e.g., Y. pestis protein(s) or fragments or fusions thereof) may be utilized. Alternatively or additionally, transgenic plants may be produced using methods well known in the art to generate stable production crops. Additionally, plants utilizing transient expression systems may be utilized for production of Y. pestis antigen(s). When utilizing plant expression systems, whether transgenic or transient expression in plants is utilized, any of nuclear expression, chloroplast expression, mitochondrial expression, or viral expression may be taken advantage of according to the applicability of the system to antigen desired. Furthermore, additional expression systems for production of antigens and fusion proteins may be utilized. For example, mammalian expression systems (e.g., mammalian cell lines (e.g., CHO, etc.)), bacterial expression systems (e.g., E. coli), insect expression systems (e.g., baculovirus), yeast expression systems, and in vitro expression systems (e.g., reticulate lysates) may be used for expression of antigens and fusion proteins.

Production and Isolation of Antigen

0182In general, standard methods known in the art may be used for culturing or growing plants, plant cells, and/or plant tissues (e.g., clonal plants, clonal plant cells, clonal roots, clonal root lines, sprouts, sprouted seedlings, plants, etc.) for production of antigen(s). A wide variety of culture media and bioreactors have been employed to culture hairy root cells, root cell lines, and plant cells (see, for example, <nplcit id="ncit0072" npl-type="s"><text>Giri et al., 2000, Biotechnol. Adv., 18:1</text></nplcit>; <nplcit id="ncit0073" npl-type="s"><text>Rao et al., 2002, Biotechnol. Adv., 20:101</text></nplcit>). Clonal plants may be grown in any suitable manner.

0183In a certain embodiments, Y. pestis antigens may be produced by any known method. In some embodiments, a Y. pestis antigen is expressed in a plant or portion thereof. Proteins are isolated and purified in accordance with conventional conditions and techniques known in the art. These include methods such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis, and the like. The present invention involves purification and affordable scaling up of production of Y. pestis antigen(s) using any of a variety of plant expression systems known in the art and provided herein, including viral plant expression systems described herein.

0184In many embodiments, it will be desirable to isolate Y. pestis antigen(s) for vaccine products. Where a protein in accordance with the invention is produced from plant tissue(s) or a portion thereof, e.g., roots, root cells, plants, plant cells, that express them, methods described in further detail herein, or any applicable methods known in the art may be used for any of partial or complete isolation from plant material. Where it is desirable to isolate an expression product from some or all of plant cells or tissues that express it, any available purification techniques may be employed. Those of ordinary skill in the art are familiar with a wide range of fractionation and separation procedures (see, for example, <nplcit id="ncit0074" npl-type="b"><text>Scopes et al., Protein Purification: Principles and Practice, 3rd Ed., Janson et al., 1993</text></nplcit>; <nplcit id="ncit0075" npl-type="b"><text>Protein Purification: Principles, High Resolution Methods, and Applications, Wiley-VCH, 1998</text></nplcit>; <nplcit id="ncit0076" npl-type="b"><text>Springer-Verlag, NY, 1993</text></nplcit>; and <nplcit id="ncit0077" npl-type="b"><text>Roe, Protein Purification Techniques, Oxford University Press, 2001</text></nplcit>). Often, it will be desirable to render a product more than about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% pure. See, e.g., <patcit id="pcit0009" dnum="US6740740B"><text>U.S. Patents 6,740,740</text></patcit> and <patcit id="pcit0010" dnum="US6841659B"><text>6,841,659</text></patcit> for discussion of certain methods useful for purifying substances from plant tissues or fluids.

0185Those skilled in the art will appreciate that a method of obtaining desired Y. pestis antigen(s) product(s) is by extraction. Plant material (e.g., roots, leaves, etc.) may be extracted to remove desired products from residual biomass, thereby increasing concentration and purity of product. Plants may be extracted in a buffered solution. For example, plant material may be transferred into an amount of ice-cold water at a ratio of one to one by weight that has been buffered with, e.g., phosphate buffer. Protease inhibitors can be added as required. Plant material can be disrupted by vigorous blending or grinding while suspended in buffer solution and extracted biomass removed by filtration or centrifugation. Product carried in solution can be further purified by additional steps or converted to a dry powder by freeze-drying or precipitation. Extraction can be carried out by pressing. Plants or roots can be extracted by pressing in a press or by being crushed as they are passed through closely spaced rollers. Fluids expressed from crushed plants or roots are collected and processed according to methods well known in the art. Extraction by pressing allows release of products in a more concentrated form. However, overall yield of product may be lower than if product were extracted in solution.

Vaccines

0186The present disclosure provides pharmaceutical antigen proteins for therapeutic use, such as Y. pestis antigen(s) (e.g., Y. pestis protein(s) or an immunogenic portion(s) thereof, or fusion proteins comprising Y. pestis protein(s) or an immunogenic portion(s) thereof), active as agents for treatment and/or prophylaxis of Y. pestis infection. Further, the disclosure provides vaccines for veterinary use, as Y. pestis antigen is active in veterinary applications. In certain embodiments, Y. pestis antigen(s) may be produced by plant(s) or portion thereof (e.g., root, cell, sprout, cell line, plant, etc.). In certain embodiments, provided Y. pestis antigens are expressed in plants, plant cells, and/or plant tissues (e.g., sprouts, sprouted seedlings, roots, root culture, clonal cells, clonal cell lines, clonal plants, etc.), and can be used directly from plant or partially purified or purified in preparation for pharmaceutical administration to a subject.

0187The present disclosure provides plants, plant cells, and plant tissues expressing Y. pestis antigen(s) that maintains pharmaceutical activity when administered to a subject in need thereof. Exemplary subjects include vertebrates (e.g., mammals such as humans). Subjects include veterinary subjects such as bovines, ovines, canines, felines, etc. In certain aspects, an edible plant or portion thereof (e.g., sprout, root) is administered orally to a subject in a therapeutically effective amount. In some aspects one or more Y. pestis antigen(s) is provided in a pharmaceutical preparation, as described herein.

0188Vaccine compositions in accordance with the disclosure comprise one or more Y. pestis antigens. In certain embodiments, at least two Y. pestis antigens are included in an administered vaccine composition.

0189According to the present invention, treatment of a subject with a Y. pestis antigen vaccine is intended to elicit a physiological effect. A vaccine protein may have healing curative or palliative properties against a disorder or disease and can be administered to ameliorate relieve, alleviate, delay onset of, reverse, and/or lessen symptoms or severity of a disease or disorder. A vaccine comprising a Y. pestis antigen may have prophylactic properties and can be used to prevent or delay the onset of a disease or to lessen the severity of such disease, disorder, or pathological condition when it does emerge. A physiological effect elicited by treatment of a subject with antigen according to the present invention can include an effective immune response such that infection by an organism is thwarted.

0190Pharmaceutical compositions in accordance with the invention can be administered therapeutically or prophylactically. Compositions may be used to treat or prevent a disease. For example, any individual who suffers from a disease (e.g. Yersinia pestis infection) or who is at risk of developing a disease may be treated. It will be appreciated that an individual can be considered at risk for developing a disease without having been diagnosed with any symptoms of a disease (e.g. Yersinia pestis infection). For example, if an individual is known to have been, or to be intended to be, in situations with relatively high risk of exposure to Y. pestis infection, that individual will be considered at risk for developing the disease. Similarly, if members of an individual's family or friends have been diagnosed with Y. pestis infection, the individual may be considered to be at risk for developing the disease. In some embodiments, if an individual has come into contact with a non-human animal that has been diagnosed with Y. pestis infection (e.g., cat, dog, mouse, rat, horse, etc.), the individual may be considered to be at risk for developing the disease.

Administration

0191Yersinia pestis antigens in accordance with the invention and/or pharmaceutical compositions thereof (e.g., vaccines) may be administered using any amount and any route of administration effective for treatment.

0192The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular composition, its mode of administration, its mode of activity, and the like. Y. pestis antigens are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific Y. pestis antigen employed; the specific pharmaceutical composition administered; the half-life of the composition after administration; the age, body weight, general health, sex, and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors, well known in the medical arts.

0193Pharmaceutical compositions of the present invention may be administered by any route. In some embodiments, pharmaceutical compositions of the present invention are administered by a variety of routes, including oral (PO), intravenous (IV), intramuscular (IM), intra-arterial, intramedullary, intrathecal, subcutaneous (SQ), intraventricular, transdermal, interdermal, intradermal, rectal (PR), vaginal, intraperitoneal (IP), intragastric (IG), topical (e.g., by powders, ointments, creams, gels, lotions, and/or drops), mucosal, intranasal, buccal, enteral, vitreal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; as an oral spray, nasal spray, and/or aerosol; and/or through a portal vein catheter. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent being administered (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate a particular mode of administration), etc.

0194In some embodiments, vaccines in accordance with the invention are delivered by multiple routes of administration (e.g., by subcutaneous injection and by intranasal inhalation). For vaccines involving two or more doses, different doses may be administered via different routes.

0195In some embodiments, vaccines in accordance with the invention are delivered by subcutaneous injection. In some embodiments, vaccines in accordance with the invention are delivered by intranasal inhalation.

0196In some embodiments, vaccines in accordance with the invention are delivered by oral and/or mucosal routes. Oral and/or mucosal delivery can prime systemic immune response. There has been considerable progress in the development of heterologous expression systems for oral administration of antigens that stimulate the mucosal-immune system and can prime systemic immunity. Previous efforts at delivery of oral vaccine however, have demonstrated a requirement for considerable quantities of antigen in achieving efficacy. Thus, economical production of large quantities of target antigens is a prerequisite for creation of effective oral vaccines. Development of plants expressing antigens, including thermostable antigens, represents a more realistic approach to such difficulties.

0197In certain embodiments, a Y. pestis antigen expressed in a plant or portion thereof is administered to a subject orally by direct administration of a plant to a subject. In some aspects a vaccine protein expressed in a plant or portion thereof is extracted and/or purified, and used for preparation of a pharmaceutical composition. It may be desirable to formulate such isolated products for their intended use (e.g., as a pharmaceutical agent, vaccine composition, etc.). In some embodiments, it will be desirable to formulate products together with some or all of plant tissues that express them.

0198Where it is desirable to formulate product together with plant material, it will often be desirable to have utilized a plant that is not toxic to the relevant recipient (e.g., a human or other animal). Relevant plant tissue (e.g., cells, roots, leaves) may simply be harvested and processed according to techniques known in the art, with due consideration to maintaining activity of the expressed product. In certain embodiments, it is desirable to have expressed Y. pestis antigen in an edible plant (and, specifically in edible portions of the plant) so that the material can subsequently be eaten. For instance, where vaccine antigen is active after oral delivery (when properly formulated), it may be desirable to produce antigen protein in an edible plant portion, and to formulate expressed Y. pestis antigen for oral delivery together with some or all of the plant material with which a protein was expressed.

0199In some embodiments, vaccines in accordance with the invention are administered by subcutaneous, intramuscular, and/or intravenous injection.

0200In certain embodiments, Y. pestis antigens in accordance with the present invention and/or pharmaceutical compositions thereof (e.g., vaccines) in accordance with the invention may be administered at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg of subject body weight per day to obtain the desired therapeutic effect. The desired dosage may be delivered more than three times per day, three times per day, two times per day, once per day, every other day, every third day, every week, every two weeks, every three weeks, every four weeks, every two months, every six months, or every twelve months. In certain embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).

0201Compositions are administered in such amounts and for such time as is necessary to achieve the desired result. In certain embodiments, a "therapeutically effective amount" of a pharmaceutical composition is that amount effective for treating, attenuating, or preventing a disease in a subject. Thus, the "amount effective to treat, attenuate, or prevent disease," as used herein, refers to a nontoxic but sufficient amount of the pharmaceutical composition to treat, attenuate, or prevent disease in any subject. For example, the "therapeutically effective amount" can be an amount to treat, attenuate, or prevent infection (e.g., viral infection, Y. pestis infection), etc.

0202It will be appreciated that Y. pestis antigens in accordance with the present invention and/or pharmaceutical compositions thereof can be employed in combination therapies. The particular combination of therapies (e.g., therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will be appreciated that the therapies employed may achieve a desired effect for the same purpose (for example, Y. pestis antigens useful for treating, preventing, and/or delaying the onset of Y. pestis infection may be administered concurrently with another agent useful for treating, preventing, and/or delaying the onset of Y. pestis infection), or they may achieve different effects (e.g., control of any adverse effects). The invention encompasses the delivery of pharmaceutical compositions in combination with agents that may improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.

0203Pharmaceutical compositions in accordance with the present invention may be administered either alone or in combination with one or more other therapeutic agents. By "in combination with," it is not intended to imply that the agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope of the invention. Compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. In will be appreciated that therapeutically active agents utilized in combination may be administered together in a single composition or administered separately in different compositions. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent.

0204In general, it is expected that agents utilized in combination with be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.

0205In certain embodiments, vaccine compositions comprise at least two Y. pestis antigens. For example, certain vaccine compositions can comprise at least two Y. pestis antigens in accordance with the invention (e.g., F1 protein and/or LcrV protein). In some aspects such combination vaccines may include one thermostable fusion protein comprising Y. pestis antigen; in some aspects, two or more thermostable fusion proteins comprising Y. pestis antigen are provided.

0206Where combination vaccines are utilized, it will be understood that any combination of Y. pestis antigens may be used for such combinations. Compositions may include multiple Y. pestis antigens, including multiple antigens provided herein. Furthermore, compositions may include one or more antigens provided herein with one or more additional antigens. Combinations of Y. pestis antigens include Y. pestis antigens derived from one or more various subtypes or strains such that immunization confers immune response against more than one infection type. Combinations of Y. pestis antigen may include at least one, at least two, at least three, at least four or more antigens derived from different subtypes or strains. In some combinations, at least two or at least three antigens from different subtypes are combined in one vaccine composition. Furthermore, combination vaccines may utilize Y. pestis antigen and antigen from one or more unique infectious agents.

Pharmaceutical Compositions and/or Formulations

0207The present disclosure provides Yersinia pestis antigens and pharmaceutical compositions comprising at least one Y. pestis antigen and at least one pharmaceutically acceptable excipient (e.g., vaccine compositions). Such pharmaceutical compositions may optionally comprise one or more additional therapeutically active substances. In accordance with some embodiments, methods of administering a pharmaceutical composition comprising administering Y. pestis antigens to a subject in need thereof are provided. In some embodiments, pharmaceutical compositions are administered to humans. For the purposes of the present disclosure, the phrase "active ingredient" generally refers to a Y. pestis antigen in accordance with the invention. In certain aspects, a Y. pestis antigen is or comprises F1 protein. In certain aspects, a Y. pestis antigen is or comprises LcrV protein.

0208Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.

0209A pharmaceutical composition in accordance with the invention may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a "unit dose" is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

0210Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.

0211Vaccines may include additionally any suitable adjuvant to enhance the immunogenicity of the vaccine when administered to a subject. For example, such adjuvant(s) may include, without limitation, extracts of Quillaja saponaria (QS), including purified subfractions of food grade QS such as Quil A and QS-21, alum, aluminum hydroxide, aluminum phosphate, MF59, Malp2, incomplete Freund's adjuvant; complete Freund's adjuvant, ALHYDROGEL®, 3 De-O-acylated monophosphoryl lipid A (3D-MPL). Further adjuvants include immunomodulatory oligonucleotides, for example unmethylated CpG sequences as disclosed in <patcit id="pcit0011" dnum="WO9602555A"><text>WO 96/02555</text></patcit>. Combinations of different adjuvants, such as those mentioned hereinabove, are contemplated as providing an adjuvant which is a preferential stimulator of TH1 cell response. For example, QS21 can be formulated together with 3D-MPL. The ratio of QS21:3D-MPL will typically be in the order of 1:10 to 10:1; 1:5 to 5:1; and often substantially 1:1. The desired range for optimal synergy may be 2.5:1 to 1:1 3D-MPL: QS21. Doses of purified QS extracts suitable for use in a human vaccine formulation are from 0.01 mg to 10 mg per kilogram of bodyweight.

0212It should be noted that certain thermostable proteins (e.g., lichenase) may themselves demonstrate immunoresponse potentiating activity, such that use of such protein whether in a fusion with a Y. pestis antigen or separately may be considered use of an adjuvant. Thus, vaccine compositions may further comprise one or more adjuvants. Certain vaccine compositions may comprise two or more adjuvants. Furthermore, depending on formulation and routes of administration, certain adjuvants may be desired in particular formulations and/or combinations.

0213Pharmaceutical formulations of the present invention may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. <nplcit id="ncit0078" npl-type="b"><text>Remington's The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro, (Lippincott, Williams & Wilkins, Baltimore, MD, 2006</text></nplcit>) discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional excipient medium is incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.

0214In some embodiments, the pharmaceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, the excipient is approved for use in humans and for veterinary use. In some embodiments, the excipient is approved by United States Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.

0215Pharmaceutically acceptable excipients used in the manufacture of pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Such excipients may optionally be included in the formulations. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and/or perfuming agents can be present in the composition, according to the judgment of the formulator.

0216Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and/or combinations thereof

0217Exemplary granulating and/or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinylpyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (VEEGUM®), sodium lauryl sulfate, quaternary ammonium compounds, etc., and/or combinations thereof.

0218Exemplary surface active agents and/or emulsifiers include, but are not limited to, natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and VEEGUM® [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g., carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate [TWEEN®20], polyoxyethylene sorbitan [TWEEN®60], polyoxyethylene sorbitan monooleate [TWEEN®80], sorbitan monopalmitate [SPAN®40], sorbitan monostearate [SPAN®60], sorbitan tristearate [SPAN®65], glyceryl monooleate, sorbitan monooleate [SPAN®80]), polyoxyethylene esters (e.g., polyoxyethylene monostearate [MYRJ®45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and SOLUTOL®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., CREMOPHOR®), polyoxyethylene ethers, (e.g., polyoxyethylene lauryl ether [BRIJ®30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, PLURONIC®F 68, POLOXAMER®188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.

0219Exemplary binding agents include, but are not limited to, starch (e.g., cornstarch, starch paste, etc.); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.); natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinylpyrrolidone), magnesium aluminum silicate [VEEGUM®], larch arabogalactan, etc.); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; etc.; and combinations thereof.

0220Exemplary preservatives may include, but are not limited to, antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and/or other preservatives. Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and/or sodium sulfite. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and/or trisodium edetate. Exemplary antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and/or thimerosal. Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and/or sorbic acid. Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and/or phenylethyl alcohol. Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and/or phytic acid. Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS®, PHENONIP®, methylparaben, GERMALL®115, GERMABEN®II, NEOLONE™, KATHON™, and/or EUXYL®.

0221Exemplary buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and/or combinations thereof.

0222Exemplary lubricating agents include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.

0223Exemplary oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and/or combinations thereof.

0224Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and/or elixirs. In addition to active ingredients, liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and/or perfuming agents. In certain embodiments for parenteral administration, compositions are mixed with solubilizing agents such a CREMOPHOR®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and/or combinations thereof.

0225Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing agents, wetting agents, and/or suspending agents. Sterile injectable preparations may be sterile injectable solutions, suspensions, and/or emulsions in nontoxic parenterally acceptable diluents and/or solvents, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid can be used in the preparation of injectables.

0226Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, and/or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

0227Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing compositions with suitable non-irritating excipients such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.

0228Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient such as sodium citrate or dicalcium phosphate and/or fillers or extenders (e.g., starches, lactose, sucrose, glucose, mannitol, and silicic acid), binders (e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia), humectants (e.g., glycerol), disintegrating agents (e.g., agar, calcium carbonate, potato starch, tapioca starch, alginic acid, certain silicates, and sodium carbonate), solution retarding agents (e.g., paraffin), absorption accelerators (e.g., quaternary ammonium compounds), wetting agents (e.g., cetyl alcohol and glycerol monostearate), absorbents (e.g., kaolin and bentonite clay), and lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate), and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.

0229Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

0230Vaccine products, optionally together with plant tissue, are particularly well suited for oral administration as pharmaceutical compositions. Oral liquid formulations can be used and may be of particular utility for pediatric populations. Harvested plant material may be processed in any of a variety of ways (e.g., air drying, freeze drying, extraction etc.), depending on the properties of the desired therapeutic product and its desired form. Such compositions as described above may be ingested orally alone or ingested together with food or feed or a beverage. Compositions for oral administration include plants; extractions of plants, and proteins purified from infected plants provided as dry powders, foodstuffs, aqueous or non-aqueous solvents, suspensions, or emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil, fish oil, and injectable organic esters. Aqueous carriers include water, water-alcohol solutions, emulsions or suspensions, including saline and buffered medial parenteral vehicles including sodium chloride solution, Ringer's dextrose solution, dextrose plus sodium chloride solution, Ringer's solution containing lactose or fixed oils. Examples of dry powders include any plant biomass that has been dried, for example, freeze dried, air dried, or spray dried. For example, plants may be air dried by placing them in a commercial air dryer at about 120°F until biomass contains less than 5% moisture by weight. Dried plants may be stored for further processing as bulk solids or further processed by grinding to a desired mesh sized powder. Alternatively or additionally, freeze-drying may be used for products that are sensitive to air-drying. Products may be freeze dried by placing them into a vacuum drier and dried frozen under a vacuum until the biomass contains less than about 5% moisture by weight. Dried material can be further processed as described herein.

0231Plant-derived material may be administered as or together with one or more herbal preparations. Useful herbal preparations include liquid and solid herbal preparations. Some examples of herbal preparations include tinctures, extracts (e.g., aqueous extracts, alcohol extracts), decoctions, dried preparations (e.g., air-dried, spray dried, frozen, or freeze-dried), powders (e.g., lyophilized powder), and liquid. Herbal preparations can be provided in any standard delivery vehicle, such as a capsule, tablet, suppository, liquid dosage, etc. Those skilled in the art will appreciate the various formulations and modalities of delivery of herbal preparations that may be applied to the present invention.

0232In some methods, a plant or portion thereof expressing a Y. pestis antigen according to the present invention, or biomass thereof, is administered orally as medicinal food. Such edible compositions are typically consumed by eating raw, if in a solid form, or by drinking, if in liquid form. The plant material can be directly ingested without a prior processing step or after minimal culinary preparation. For example, a vaccine antigen may be expressed in a sprout which can be eaten directly. For instance, vaccine antigens expressed in an alfalfa sprout, mung bean sprout, or spinach or lettuce leaf sprout, etc. In some embodiments, plant biomass may be processed and the material recovered after the processing step is ingested.

0233Processing methods useful in accordance with the present invention are methods commonly used in the food or feed industry. Final products of such methods typically include a substantial amount of an expressed antigen and can be conveniently eaten or drunk. The final product may be mixed with other food or feed forms, such as salts, carriers, favor enhancers, antibiotics, and the like, and consumed in solid, semi-solid, suspension, emulsion, or liquid form. Such methods can include a conservation step, such as, e.g., pasteurization, cooking, or addition of conservation and preservation agents. Any plant may be used and processed in the present invention to produce edible or drinkable plant matter. The amount of Y. pestis antigen in a plant-derived preparation may be tested by methods standard in the art, e.g., gel electrophoresis, ELISA, or western blot analysis, using a probe or antibody specific for product. This determination may be used to standardize the amount of vaccine antigen protein ingested. For example, the amount of vaccine antigen may be determined and regulated, for example, by mixing batches of product having different levels of product so that the quantity of material to be drunk or eaten to ingest a single dose can be standardized. A contained, regulatable environment in accordance with the invention, however, should minimize the need to carry out such standardization procedures.

0234A vaccine protein produced in a plant cell or tissue and eaten by a subject may be preferably absorbed by the digestive system. One advantage of the ingestion of plant tissue that has been only minimally processed is to provide encapsulation or sequestration of the protein in cells of the plant. Thus, product may receive at least some protection from digestion in the upper digestive tract before reaching the gut or intestine and a higher proportion of active product would be available for uptake.

0235Dosage forms for topical and/or transdermal administration of a compound in accordance with this invention may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches. Generally, the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable excipient and/or any needed preservatives and/or buffers as may be required. Additionally, the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms may be prepared, for example, by dissolving and/or dispensing the compound in the proper medium. Alternatively or additionally, the rate may be controlled by either providing a rate controlling membrane and/or by dispersing the compound in a polymer matrix and/or gel.

0236Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices such as those described in <patcit id="pcit0012" dnum="US4886499A"><text>U.S. Patents 4,886,499</text></patcit>; <patcit id="pcit0013" dnum="US5190521A"><text>5,190,521</text></patcit>; <patcit id="pcit0014" dnum="US5328483A"><text>5,328,483</text></patcit>; <patcit id="pcit0015" dnum="US5527288A"><text>5,527,288</text></patcit>; <patcit id="pcit0016" dnum="US4270537A"><text>4,270,537</text></patcit>; <patcit id="pcit0017" dnum="US5015235A"><text>5,015,235</text></patcit>; <patcit id="pcit0018" dnum="US5141496A"><text>5,141,496</text></patcit>; and <patcit id="pcit0019" dnum="US5417662A"><text>5,417,662</text></patcit>. Intradermal compositions may be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in <patcit id="pcit0020" dnum="WO9934850A"><text>PCT publication WO 99/34850</text></patcit> and functional equivalents thereof. Jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in <patcit id="pcit0021" dnum="US5480381A"><text>U.S. Patents 5,480,381</text></patcit>; <patcit id="pcit0022" dnum="US5599302A"><text>5,599,302</text></patcit>; <patcit id="pcit0023" dnum="US5334144A"><text>5,334,144</text></patcit>; <patcit id="pcit0024" dnum="US5993412A"><text>5,993,412</text></patcit>; <patcit id="pcit0025" dnum="US5649912A"><text>5,649,912</text></patcit>; <patcit id="pcit0026" dnum="US5569189A"><text>5,569,189</text></patcit>; <patcit id="pcit0027" dnum="US5704911A"><text>5,704,911</text></patcit>; <patcit id="pcit0028" dnum="US5383851A"><text>5,383,851</text></patcit>; <patcit id="pcit0029" dnum="US5893397A"><text>5,893,397</text></patcit>; <patcit id="pcit0030" dnum="US5466220A"><text>5,466,220</text></patcit>; <patcit id="pcit0031" dnum="US5339163A"><text>5,339,163</text></patcit>; <patcit id="pcit0032" dnum="US5312335A"><text>5,312,335</text></patcit>; <patcit id="pcit0033" dnum="US5503627A"><text>5,503,627</text></patcit>; <patcit id="pcit0034" dnum="US5064413A"><text>5,064,413</text></patcit>; <patcit id="pcit0035" dnum="US5520639A"><text>5,520,639</text></patcit>; <patcit id="pcit0036" dnum="US4596556A"><text>4,596,556</text></patcit>; <patcit id="pcit0037" dnum="US4790824A"><text>4,790,824</text></patcit>; <patcit id="pcit0038" dnum="US4941880A"><text>4,941,880</text></patcit>; <patcit id="pcit0039" dnum="US4940460A"><text>4,940,460</text></patcit>; and <patcit id="pcit0040" dnum="WO9737705A"><text>PCT publications WO 97/37705</text></patcit> and <patcit id="pcit0041" dnum="WO9713537A"><text>WO 97/13537</text></patcit>. Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable. Alternatively or additionally, conventional syringes may be used in the classical mantoux method of intradermal administration.

0237Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions. Topically administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein.

0238A pharmaceutical composition in accordance with the invention may be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 nm to about 7 nm or from about 1 nm to about 6 nm. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder and/or using a self propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nm and at least 95% of the particles by number have a diameter less than 7 nm. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nm and at least 90% of the particles by number have a diameter less than 6 nm. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.

0239Low boiling propellants generally include liquid propellants having a boiling point of below 65 °F at atmospheric pressure. Generally the propellant may constitute 50% to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1% to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).

0240Pharmaceutical compositions in accordance with the invention formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension. Such formulations may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface-active agent, and/or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration may have an average diameter in the range from about 0.1 nm to about 200 nm.

0241Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 µm to 500 µm. Such a formulation is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close to the nose.

0242Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein. A pharmaceutical composition in accordance with the invention may be prepared, packaged, and/or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1% to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 nm to about 200 nm, and may further comprise one or more of the additional ingredients described herein.

0243A pharmaceutical composition in accordance with the invention may be prepared, packaged, and/or sold in a formulation suitable for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1/1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid excipient. Such drops may further comprise buffering agents, salts, and/or one or more other of the additional ingredients described herein. Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this invention.

0244In certain situations, it may be desirable to prolong the effect of a vaccine by slowing the absorption of one or more components of the vaccine product (e.g., protein) that is subcutaneously or intramuscularly injected. This may be accomplished by use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of product then depends upon its rate of dissolution, which in turn, may depend upon size and form. Alternatively or additionally, delayed absorption of a parenterally administered product is accomplished by dissolving or suspending the product in an oil vehicle. Injectable depot forms are made by forming microcapsule matrices of protein in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of product to polymer and the nature of the particular polymer employed, rate of release can be controlled. Examples of biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations may be prepared by entrapping product in liposomes or microemulsions, which are compatible with body tissues. Alternative polymeric delivery vehicles can be used for oral formulations. For example, biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, etc., can be used. Antigen(s) or an immunogenic portions thereof may be formulated as microparticles, e.g., in combination with a polymeric delivery vehicle.

0245General considerations in the formulation and/or manufacture of pharmaceutical agents may be found, for example, in <nplcit id="ncit0079" npl-type="b"><text>Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005</text></nplcit>.

Kits

0246In some aspects, the present disclosure provides pharmaceutical packs or kits including Yersinia pestis antigens according to the present disclosure. In certain aspects, pharmaceutical packs or kits include live sprouted seedlings, clonal entity or plant producing a Y. pestis antigen according to the present disclosure, or preparations, extracts, or pharmaceutical compositions containing vaccine in one or more containers filled with optionally one or more additional ingredients of pharmaceutical compositions in accordance with the disclosure. In some aspects, pharmaceutical packs or kits include pharmaceutical compositions comprising purified Y. pestis antigen according to the present disclosure, in one or more containers optionally filled with one or more additional ingredients of pharmaceutical compositions in accordance with the disclosure. In certain aspects, the pharmaceutical pack or kit includes an additional approved therapeutic agent (e.g., Y. pestis antigen, Y. pestis vaccine) for use as a combination therapy. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical products, which notice reflects approval by the agency of manufacture, use, or sale for human administration.

0247Kits are provided that include therapeutic reagents. As but one non-limiting example, Y. pestis vaccine can be provided as oral formulations and administered as therapy. Alternatively or additionally, Y. pestis vaccine can be provided in an injectable formulation for administration. In some aspects, Y. pestis vaccine can be provided in an inhalable formulation for administration. Pharmaceutical doses or instructions therefor may be provided in the kit for administration to an individual suffering from or at risk for Y. pestis infection.

0248The representative examples that follow are intended to help illustrate the invention and are not intended to, nor should they be construed to, limit the scope of the invention which is limited by the appended claims. Indeed, various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples which follow and the references to the scientific and patent literature cited herein. The following examples contain information, exemplification and guidance, which can be adapted to the practice of this invention in its various embodiments and the equivalents thereof.

Exemplification

Example 1. A Plant-Produced Plague Vaccine Candidate Confers Protection to Monkeys

0249Y. pestis proteins F1 and LcrV were independently fused to an engineered version of the thermostable enzyme lichenase (LicKM) from Clostridium thermocellum (<nplcit id="ncit0080" npl-type="s"><text>Musiychuk et al., 2007, Influenza Other Respir. Viruses, 1:19-25</text></nplcit>; incorporated herein by reference). Fusions were produced in Nicotiana benthamiana and evaluated in Cynomolgus Macaques for immunogenicity and protective efficacy. When administered to monkeys, a mixture of the LicKM fusions to F1 and LcrV was highly immunogenic and protective.

Materials and Methods

Engineering, expression and purification of

Y. pestis

antigens

0250The LicKM fusion system for producing antigens in plants is described (<nplcit id="ncit0081" npl-type="s"><text>Musiychuk et al., 2007, Influenza Other Respir. Viruses, 1:19-25</text></nplcit>; incorporated herein by reference). Briefly, sequence encoding full-length mature Y. pestis F1 and LcrV were separately cloned into LicKM (GenBank accession number DQ776900) as in-frame fusions to obtain LicKM-F1 and LicKM-LcrV. LicKM-F1 and LicKM-LcrV were individually cloned in the plant expression vector pBID4 to give pBID4-LicKM-F1 and pBID4-LicKM-LcrV, respectively, which were then separately introduced into the Agrobacterium rhizogenes strain A4. To produce each target antigen, A. rhizogenes strains carrying pBID4-LicKM-F1 and pBID4-LicKM-LcrV were inoculated into N. benthamiana, and leaf tissue was harvested 5 days later. Target antigens were purified from homogenized leaves by affinity chromatography followed by ion exchange chromatography. Purified antigens were characterized by SDS-PAGE followed by immunoblotting. To provide control material, LicKM alone was similarly expressed in and purified from N. benthamiana.

Cynomolgus Macaques challenge study using plant-produced

Y. pestis

antigens

0251The study was conducted using female Cynomolgus Macaques (Covance Research Products) of approximately 2 years of age and approximately 2 kg weight. For test groups, LicKM-F1 and LicKM-LcrV were mixed at a weight ratio of 1:1 to give the candidate vaccine (CV). Where antigens were to be delivered with adjuvant, they were mixed with 2% ALHYDROGEL® (Accurate Chemical & Scientific Corporation) at a ratio of 1:50 (w/w; antigen/adjuvant). The study comprised four groups: Group 1 (negative control) had two animals and groups 2-4 had three animals per group. Group 1 received 125 µg/dose of LicKM plus adjuvant. Group 2 received 25 µg/dose of CV plus adjuvant. Group 3 received 250 µg/dose of CV plus adjuvant, and group 4 received 250 µg/dose of CV alone. Antigens were administered by subcutaneous injection on study days 1, 14, and 28. Serum samples were collected on days of candidate vaccine administration and 7 days after the final administration. Animals were challenged via nose-only inhalation with Y. pestis strain CO 92; Biovar-Orientalis at 100 × LD50 on study day 40 and observed for a further 14 days.

Analysis of serum samples for immune responses to administered antigens

0252Sera collected from immunized monkeys were analyzed for the presence of LcrV-and F1-specific IgG and IgA by ELISA. MaxiSorp 96-well plates (Nunc) were coated with 1 µg/ml Escherichia coli-produced F1 fused to domain 1 of Bacillus anthracis lethal factor (LFD1) or E. coli-produced LcrV. Serum samples were added at an initial dilution of 1:100, titrated in five-fold dilutions, and target-specific antibodies were detected using goat anti-monkey IgG (KPL) or IgA (Fitzgerald Industries International Inc.) conjugated to HRP.

Analysis of tissue pathogen load

0253Tissues from all challenged animals were evaluated for presence of Y. pestis. Tissues were placed in 1% peptone and individually homogenized. Tissue homogenates were serially diluted in 1% peptone, and 100 µl aliquots were spread plated on 90 mm tryptic soy agar (TSA) plates in triplicate. TSA plates were incubated at 28°C for 36 h- 48 h, after which Y. pestis colonies were counted. Pathogen load is expressed as colony forming units (CFU).

Results

0254Expression of Y. pestis F1 and LcrV antigens as fusions to LicKM in N. benthamiana

0255LicKM, LicKM-F1, and LicKM-LcrV were purified from N. benthamiana leaf tissue and analyzed by SDS-PAGE and immunoblot (<figref idref="f0025">Figure 2</figref>). Gels were stained with Coomassie Brilliant Blue to show purified LicKM, LicKM-F1, and LicKM-LcrV (<figref idref="f0025">Figure 2A</figref>). On average, 380 µg LicKM-F1 and 120 µg of LicKM-LcrV was purified per gram of fresh leaf tissue. In immunoblot assays, antibodies specific for LicKM reacted with LicKM and both fusion proteins (<figref idref="f0025">Figure 2B</figref>), whereas antibodies specific for either LcrV (<figref idref="f0025">Figure 2C</figref>) or F1 (<figref idref="f0025">Figure 2D</figref>) reacted only with their respective LicKM fusion proteins.

Immunogenicity and protective efficacy of plant produced F1 and LcrV

0256To evaluate immunogenicity and protective efficacy of plant-produced antigens, animals were immunized with a mixture of LicKM-F1 and LicKM-LcrV or with LicKM alone. Serum samples were assessed for the presence of IgG and IgA specific to LcrV and F1. All animals in group 3 mounted a strong IgG response against both LcrV (<figref idref="f0026">Figure 3A</figref>) and F1 (<figref idref="f0026">Figure 3B</figref>). IgG antibody titers against LcrV approached peak values following the priming dose and did not substantially increase following booster doses. In group 4, which received the same dose of antigen but in the absence of adjuvant, IgG responses specific to LcrV were up to two logs lower than group 3 following the priming dose and remained significantly lower than group 3 even after booster doses (<figref idref="f0026">Figure 3A</figref>). Also, the IgG response to F1 in group 4 was negligible, even after the two boosts (<figref idref="f0026">Figure 3B</figref>). These results indicate that adjuvant can help stimulate high titer antibody responses. Animals in group 2 that were immunized with 10-fold less antigen in the presence of adjuvant produced anti-LcrV antibodies with titers as high as group 3 (<figref idref="f0026">Figure 3A</figref>). However, F1-specific IgG titers in this group were approximately two logs lower than group 3 (<figref idref="f0026">Figure 3B</figref>). Production of serum LcrV-specific IgA was detected at similar levels in animals in groups 2 and 3 and peaked after the prime (<figref idref="f0026">Figure 3C</figref>). Group 4 animals produced detectable amounts of serum IgA against LcrV (<figref idref="f0026">Figure 3C</figref>), although at lower titers than observed in groups 2 and 3. In all test groups, F1-specific serum IgA responses were lower than LcrV-specific IgA responses and were not measurable in all animals (<figref idref="f0026">Figure 3D</figref>). No LcrV- or F1-specific antibodies were detected in control animals.

0257Following immunization, vaccinated animals were challenged with aerosolized Y. pestis. All animals in group 1 developed clinical signs of disease and succumbed to death 5 days after challenge (<figref idref="f0026">Figure 3E</figref>). By contrast, all animals in group 3 survived the challenge, indicating that the plant-produced LicKMF1/LicKM-LcrV antigen mixture is fully protective. Two of the three animals in group 2 survived the challenge but, none of the animals in group 4 survived (<figref idref="f0026">Figure 3E</figref>). Post-mortem analysis of pathogen load in different organs of animals that survived the challenge revealed no Y. pestis, whereas organs collected from animals that died of challenge had high titers of bacteria (Table 2). <tables id="tabl0002" num="0002"><table frame="all"><title>Table 2. Tissue Pathogen Load (CFU) in Monkeys Following Y. pestis Challenge</title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="25mm" /><colspec colnum="2" colname="col2" colwidth="26mm" /><colspec colnum="3" colname="col3" colwidth="23mm" /><colspec colnum="4" colname="col4" colwidth="26mm" /><colspec colnum="5" colname="col5" colwidth="23mm" /><thead><row><entry align="center" valign="middle">Group</entry><entry align="center" valign="middle">Spleen</entry><entry align="center" valign="middle">Liver</entry><entry align="center" valign="middle">Lymph Node</entry><entry align="center" valign="middle">Lung</entry></row></thead><tbody><row><entry morerows="1" align="center" valign="middle">1</entry><entry align="center" valign="middle">> 2 × 106</entry><entry align="center" valign="middle">> 2.5 × 106</entry><entry align="center" valign="middle">> 6.8 × 106</entry><entry align="center" valign="middle">> 7.4 × 106</entry></row><row><entry align="center" valign="middle">> 2 × 106</entry><entry align="center" valign="middle">> 2 106</entry><entry align="center" valign="middle">> 1.1 × 107</entry><entry align="center" valign="middle">> 2.3 × 106</entry></row><row><entry morerows="2" align="center" valign="middle">2</entry><entry align="center" valign="middle">> 2 × 106</entry><entry align="center" valign="middle">> 2 × 106</entry><entry align="center" valign="middle">> 2 × 106</entry><entry align="center" valign="middle">> 2 × 106</entry></row><row><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry></row><row><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry></row><row><entry morerows="2" align="center" valign="middle">3</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry></row><row><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry></row><row><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry><entry align="center" valign="middle">0</entry></row><row><entry morerows="2" align="center" valign="middle">4</entry><entry align="center" valign="middle">3.3 × 106</entry><entry align="center" valign="middle">5.8 × 106</entry><entry align="center" valign="middle">3.6 × 108</entry><entry align="center" valign="middle">> 4 × 109</entry></row><row><entry align="center" valign="middle">> 2 × 106</entry><entry align="center" valign="middle">> 3.1 × 106</entry><entry align="center" valign="middle">> 9.9 × 106</entry><entry align="center" valign="middle">> 2.9 × 106</entry></row><row><entry align="center" valign="middle">2 × 109</entry><entry align="center" valign="middle">4.4 × 108</entry><entry align="center" valign="middle">1.3 × 109</entry><entry align="center" valign="middle">> 8.3 × 109</entry></row></tbody></tgroup></table></tables>

0258In summary, plant-produced antigens stimulated strong antibody responses and provided full protection against challenge with aerosolized Y. pestis in primates. The present invention encompasses the recognition that plant-produced Y. pestis antigens may stimulate strong antibody responses and provide full or partial protection against Y. pestis infection in humans, non-human primates, and other mammals (e.g., cats, dogs, mice, rats, horses, cows, etc.).

Example 2. A Plant-Produced Plague Double Fusion Vaccine Candidate Stimulates High Titers of Antigen-Specific IgG and Confers Protection to Mammals

0259Y. pestis proteins F 1 and LcrV were both fused to an engineered version of the thermostable enzyme lichenase (LicKM) from Clostridium thermocellum (<nplcit id="ncit0082" npl-type="s"><text>Musiychuk et al., 2007, Influenza Other Respir. Viruses, 1:19-25</text></nplcit>; incorporated herein by reference). LcrV protein was fused into the loop region of LicKM, and F1 protein was fused to the C-terminus of LicKM. Fusions were produced in Nicotiana benthamiana, and serum LcrV- and F1-specific IgG titers were measured. Fusions were also evaluated in Cynomolgus Macaques for immunogenicity and protective efficacy. When administered to monkeys, the double fusion generated high LcrV- and F1-specific IgG titers, and the double fusion was found to be highly immunogenic and protective.

Engineering, expression, and purification of

Y. pestis

double fusion antigen

0260The LicKM fusion system for producing antigens in plants is described (<nplcit id="ncit0083" npl-type="s"><text>Musiychuk et al., 2007, Influenza Other Respir. Viruses, 1:19-25</text></nplcit>; incorporated herein by reference). Briefly, sequence encoding full-length mature Y. pestis F1 and LcrV were both cloned into LicKM (GenBank accession number DQ776900) as in-frame fusions to obtain LcrV-F1-LicKM. LcrV was cloned into the loop region of LicKM, and F1 was fused to the C-terminus of LicKM.

0261The nucleotide sequence of the double fusion construct, which encodes the double fusion protein antigen, is: <img file="EP2178558B1_D0014.tif" /><img file="EP2178558B1_D0015.tif" /> The plain text sequences correspond to LicKM sequences (e.g., CAG...GGT, SEQ ID NO: 12; and GGT...TAC, SEQ ID NO: 13), a 6x-His tag (i.e., 5' CATCATCATCATCACCAC 3' SEQ ID NO: 14), and an ER retention signal (i.e., 5' AAGGATGAGCTT 3' SEQ ID NO: 15). The bold, underlined sequence ATG...GCT (SEQ ID NO: 16) corresponds to the PR1a signal peptide. The bold, underlined sequence ATG...AAG (SEQ ID NO: 17) corresponds to LcrV protein coding sequence. The bold, underlined sequence GCT...CAG (SEQ ID NO: 18) corresponds to F1 protein coding sequence. The bold, italicized sequence GGATCCTTAATTAA (SEQ ID NO: 19) corresponds to a BamHI site (i.e., GGATCC, SEQ ID NO: 20) and a PacI site (i.e., TTAATTAA, SEQ ID NO: 18). The bold, italicized sequence AGACTC (SEQ ID NO: 21) corresponds to a BgIII site. The bold, italicized sequence AAGCTT (SEQ ID NO: 22) corresponds to a HindIII site. The bold, italicized sequences GTCGAC (SEQ ID NO: 23) correspond to two SalI sites. The bold, italicized sequence CTCGAGCTC (SEQ ID NO: 24) corresponds to an XhoI site (i.e., CTCGAG, SEQ ID NO: 25) and a SacI site (i.e., GAGCTC, SEQ ID NO: 26).

0262The amino acid sequence of the double fusion protein antigen is: <img file="EP2178558B1_D0016.tif" /> The plain text sequences correspond to LicKM sequences (e.g., QNG...PNG, SEQ ID NO: 28; and VVN...REY, SEQ ID NO: 29), a 6x-His tag (i.e., HHHHHH, SEQ ID NO: 30), and an ER retention signal (i.e., KDEL; SEQ ID NO: 31). The bold, underlined sequence MGF...CRA (SEQ ID NO: 32) corresponds to the PR1a signal peptide. The bold, underlined sequence MIR...SGK (SEQ ID NO: 33) corresponds to LcrV protein coding sequence. The bold, underlined sequence ADL...SNQ (SEQ ID NO: 34) corresponds to F1 protein coding sequence. The bold, italicized sequence RS (SEQ ID NO: 35) corresponds to a BglII site. The bold, italicized sequence KL (SEQ ID NO: 36) corresponds to a HindIII site. The bold, italicized sequences VD (SEQ ID NO: 37) correspond to two SalI sites.

To provide control material, LicKM alone was similarly expressed in and purified

from N. benthamiana.

0263LicKM-F1 and LicKM-LcrV were individually cloned in the plant expression vector pGREENII to give pGREEN-LcrV-F1-LicKM, which was introduced into Agrobacterium rhizogenes. A. rhizogenes were inoculated into N. benthamiana, and leaf tissue was harvested (e.g., about 5 days later). Target antigens were purified from homogenized leaves by chromatography steps (e.g., affinity chromatography followed by ion exchange chromatography). Purified antigens were characterized by Coomassie brilliant blue staining and by SDS-PAGE followed by immunoblotting. To provide control material, LicKM alone was similarly expressed in and purified from N. benthamiana.

Cynomolgus Macaques challenge study using plant-produced

Y. pestis

antigens

0264Five groups of female monkeys (five in Groups 1 and 3, eight in Group 2 and 4, and four in Group 5) each received either a vaccination as outlined in Table 3. Monkeys received each dose on Study Days 1, 14, and 28 using modes of administration specified in Table 3. <tables id="tabl0003" num="0003"><table frame="all"><title>Table 3. Double Fusion Vaccine Administration</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="17mm" /><colspec colnum="2" colname="col2" colwidth="46mm" /><colspec colnum="3" colname="col3" colwidth="56mm" /><colspec colnum="4" colname="col4" colwidth="48mm" /><thead><row><entry align="center" valign="middle" /><entry align="center" valign="middle">Vaccine Composition</entry><entry align="center" valign="middle">Dose</entry><entry align="center" valign="middle">Route and Frequency</entry></row></thead><tbody><row><entry>Group 1</entry><entry>LicKM alone</entry><entry>125 µg + ALHYDROGEL® + QuilA</entry><entry>subcutaneous injection, thrice</entry></row><row><entry>Group 2</entry><entry>LicKM-F1 + LicKM-LcrV</entry><entry>250 µg + ALHYDROGEL® + QuilA</entry><entry>subcutaneous injection, thrice</entry></row><row rowsep="0"><entry>Group 3</entry><entry>Lic KM alone</entry><entry>(a) 125 µg + ALHYDROGEL® + QuilA</entry><entry>(a) subcutaneous, once</entry></row><row><entry /><entry /><entry>(b) 125 µg (no adjuvant)</entry><entry>(b) intranasal, second and third</entry></row><row rowsep="0"><entry>Group 4</entry><entry>LicKM-F1 + LicKM-LcrV</entry><entry>(a) 250 µg + ALHYDROGEL® + QuilA</entry><entry>(a) subcutaneous, once</entry></row><row><entry /><entry /><entry>(b) 250 µg (no adjuvant)</entry><entry>(b) intranasal, second and third</entry></row><row><entry>Group 5</entry><entry>LcrV-F1-LicKM double fusion</entry><entry>250 µg + ALHYDROGEL® + QuilA</entry><entry>subcutaneous injection, thrice</entry></row></tbody></tgroup></table></tables>

0265All monkeys were challenged via inhalation with a multiple LD50 inhalation dose of Y. pestis on Study Day 40. Monkeys were evaluated for 14 days post pathogen challenge for disease development and mortality. Evaluations during the study included twice daily clinical observations and qualitative assessment of food consumption. Body weights were obtained at predetermined times during the experiment as were blood pressure measurements and radiographs. A physical examination of each monkey was conducted by a licensed veterinary technician under the supervision of a veterinarian prior to initiation of vaccination, before pathogen challenge, and prior to euthanasia. Subcutaneous body temperatures were obtained twice daily during the study beginning on Study Day 7. Serum samples were obtained periodically to assess antibody titers. Vaginal wash specimens were obtained periodically during the study to assess mucosal antibody titers. Clinical pathology (e.g., hematology and serum chemistry) was assessed periodically pre- and post-challenge. Y. pestis load was determined in whole blood at defined intervals. Selected tissues from dead or euthanized animals were also evaluated for Y. pestis load. Tissue specimens were obtained from all animals and preserved in 10% buffered formalin. Selected tissues were evaluated for histopathology.

Results and Discussion

Expression of

Y. pestis

F1 and LcrV antigens as a double fusion to LicKM

0266LcrV-F1-LicKM was purified from N. benthamiana leaf tissue and analyzed by SDS-PAGE and immunoblot (<figref idref="f0027">Figure 4</figref>, lanes 5-8). Gels were stained with Coomassie Brilliant Blue to show purified LcrV-F1-LicKM (<figref idref="f0027">Figure 4</figref>, lanes 1-4). In immunoblot assays, antibodies specific for LicKM reacted with LicKM, with the double fusion protein, and with a fusion of LicKM to an unrelated protein (i.e., anthrax lethal factor (LF) protein) (<figref idref="f0027">Figure 4</figref>).

Immunogenicity and protective efficacy of plant produced F1-LcrV-LicKM

0267To evaluate immunogenicity and protective efficacy of plant-produced F1-LcrV-LicKM double fusion antigens, animals were immunized with the double fusion, with a mixture of LicKM-F 1 and LicKM-LcrV, or with LicKM alone (see Table 3). Serum samples were assessed at Study Days -9 (i.e., 9 days prior to the first immunization dose), 14, 28, and 35 for the presence of IgG specific to LcrV and F1. All animals in Group 2 (i.e., mixture of LicKM-F1 and LicKM-LcrV plus two adjuvants administered thrice by subcutaneous injection) and Group 5 (i.e., F1-LcrV-LicKM double fusion plus two adjuvants) mounted strong IgG responses against both LcrV (<figref idref="f0028">Figures 5A and 5C</figref>) and F 1 (<figref idref="f0028">Figures 5B and 5D</figref>). Immune responses mounted by animals in Group 1 (i.e., LicKM alone plus two adjuvants) were 1 - 2 logs lower than those mounted by animals in Group 2 or Group 5 after the first immunization dose.

0268Following immunization, vaccinated animals were challenged with aerosolized Y. pestis. All five animals in Group 1 developed clinical signs of disease and succumbed to death or were considered moribund (and were, therefore, euthanized) within 9 days after challenge (i.e., about 0% survival). By contrast, seven of eight animals in Group 2 survived the challenge (i.e., about 88% survival). Three of four monkeys in Group 3 died (i.e., about 75% survival). Five of eight monkeys in Group 4 were found dead or were considered moribund (and were, therefore, euthanized) within 6 days after challenge (i.e., about 38% survival). All five monkeys in Group 5 survived to the end of the study (i.e., about 100% survival). Survival data are summarized in <figref idref="f0029">Figure 6</figref>.

0269At study initiation, all monkeys were below the level of detection for Y. pestis. Post-pathogen exposure, all monkeys that did not survive to study termination were bacteremic. Group 1: By post-immunization day 2 bacteria was detected in one of five monkeys and by post-immunization day 3 two of five were bacteremic. Bacteria were not detected in the blood of the remaining three monkeys although as discussed below, pathogen was cultured from their tissues. Group 2: Only one monkey in this group did not to survive to study termination. Bacteria were not found in its blood, but there was substantial tissue tropism. The remaining monkeys in this group had pathogen levels below the detectable level (except one monkey displayed small but transient presence on post-immunization day 4). Group 3: Three of the four monkeys exposed to the pathogen had detectable blood levels of Y. pestis. One monkey had no detectable levels of Y. pestis. Pathogen was not detected in any of the tissues taken at study termination. Group 4: The five monkeys that did not survive to the end of the study had bacteria in their blood, and the three monkeys that survived to study termination were below the level of pathogen detection. Group 5: All four monkeys in this group survived to study termination with no detectable blood levels of pathogen.

0270All monkeys that did not survive to the end of the study (i.e., monkeys that did not survive to post-immunization day 14) exhibited tissue pathogen loads in all of the tissues evaluated. Pathogen tropism was most evident for lymph nodes and lung. For monkeys that survived to post-immunization day 14, there was no detectable pathogen in the evaluated tissues.

0271In summary, plant-produced F1-LcrV-LicKM double fusion protein antigens stimulated strong antibody responses and provided 100% protection against challenge with aerosolized Y. pestis in primates. The present invention encompasses the recognition that results obtained in mammals (e.g., primates) can be predictive of therapeutic and/or prophylactic efficacy in humans. The present invention encompasses the recognition that plant-produced Y. pestis antigens may stimulate strong antibody responses and provide full or partial protection against Y. pestis infection in humans, non-human primates, and other mammals (e.g., cats, dogs, mice, rats, horses, cows, etc.).

Equivalents and Scope

0272In the claims articles such as "a," "an," and "the" may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. Furthermore, it is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Furthermore, where the claims recite a composition, it is to be understood that methods of using the composition for any of the purposes disclosed herein are included, and methods of making the composition according to any of the methods of making disclosed herein or other methods known in the art are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.

Every citation, both waysCites: the store holds 3 of 4

Citations
Document	Relation	Office
WO03057834A2	Cites	World Intellectual Property Organization (WIPO)
WO2005026375A2	Cites	World Intellectual Property Organization (WIPO)
WO2007095318A2	Cites	World Intellectual Property Organization (WIPO)
ALVAREZ M L ET AL: "Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice", VACCINE, ELSEVIER LTD, GB, vol. 24, no. 14, 24 March 2006 (2006-03-24), pages 2477-2490, XP028010560, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2005.12.057 [retrieved on 2006-03-24]	Non-patent	–
METT, V. ET AL.: 'A plant-produced plague vaccine candidate confers protection to monkeys' VACCINE vol. 25, no. 16, 20 April 2007, pages 3014 - 3017, XP022004283	Non-patent	–
SANTI, V. ET AL.: 'Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system' PROC. NATL. ACAD. SCI. vol. 103, no. 4, 24 January 2006, pages 861 - 866, XP008129743	Non-patent	–
METT, V. ET AL.: 'A plant-produced influenza subunit vaccine protects ferrets against virus challenge' INFLUENZA AND OTHER RESPIRATORY VIRUSES vol. 2, no. 1, January 2008, pages 33 - 40, XP009098809	Non-patent	–
MUSIYCHUK, K. ET AL.: 'A launch vector for the production of vaccine antigens in plants' INFLUENZA AND OTHER RESPIRATORY VIRUSES vol. 1, no. 1, January 2007, pages 19 - 25, XP009058889	Non-patent	–

13 members in 4 offices

This recordMember, by publication datePriority claim

Priority claims7

Priority claims
Document	Office	Kind	Date
949115P	United States of America	–	2007-07-11
94911507	United States of America	P	2007-07-11
2008069860	United States of America	W	2008-07-11
2008069860	–	–	–
949115P	–	–	–
US20070949115P	–	–	–
WO2008US69860	–	–	–

Members13

Family members, oldest first
Document	Office	Kind
CA2692933A1	Canada	A1	2009-01-15
WO2009009759A2	World Intellectual Property Organization (WIPO)	A2	2009-01-15
WO2009009759A9	World Intellectual Property Organization (WIPO)	A9	2009-06-04
WO2009009759A3	World Intellectual Property Organization (WIPO)	A3	2009-07-16
WO2009009759A3	World Intellectual Property Organization (WIPO)	A3	2009-07-16
EP2178558A2	European Patent Office (EPO)	A2	2010-04-28
US2011027304A1	United States of America	A1	2011-02-03
EP2178558A4	European Patent Office (EPO)	A4	2013-03-06
US8404252B2	United States of America	B2	2013-03-26
US2013149327A1	United States of America	A1	2013-06-13
EP2178558B1This record	European Patent Office (EPO)	B1	2014-04-30
US8945580B2	United States of America	B2	2015-02-03
CA2692933C	Canada	C	2016-10-18

78 legal events, as 9 offices reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code	Office
2025-07-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2025-04-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2025-04-25	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2025-04-11	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2025-03-26	Gb: european patent ceased through non-payment of renewal feeCeasedGBPC	GBPC	EP
2025-02-01	Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119	R119	DE
2023-11-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2023-11-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2023-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2023-10-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2023-06-28	Opt-out of the competence of the unified patent court (upc) registeredP01	P01	EP
2021-03-03	Change of representativeR082	R082	DE
2018-07-26	Fee paymentPLFP	PLFP	FR
2017-07-26	Fee paymentPLFP	PLFP	FR
2016-07-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2016-07-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2016-07-26	Fee paymentPLFP	PLFP	FR
2016-06-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2016-04-29	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-05-13	No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097	R097	DE
2015-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-04-08	No opposition filedOpposition26N	26N	EP
2015-03-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-03-06	No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE	PLBE	EP
2015-03-06	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA	STAA	EP
2015-02-27	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-02-27	Patent ceasedCeasedPL	PL	CH
2015-02-02	No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097	R097	DE
2015-01-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-01-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-01-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-01-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-01-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2015-01-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-12-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-11-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-11-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-11-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-11-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-11-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-11-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-10-08	Discontinued in the netherlands as no translation has been filedVDEP	VDEP	NL
2014-09-25	Invalidated european patentMG4D	MG4D	LT
2014-09-15	Deletion acc. to par. 5 (withdrawal of the translation of the ep patent)MK05	MK05	AT
2014-06-12	Dpma publication of mentioned ep patent grantGrantedR096	R096	DE
2014-05-21	European patents granted designating irelandGrantedFG4D	FG4D	IE
2014-05-15	Reference to at number (ep patent validated in austria)REF	REF	AT
2014-04-30	Designated contracting statesAK	AK	EP
2014-04-30	European patent takes effect as a national patent in ch/liEP	EP	CH
2014-04-30	European patent grantedGrantedFG4D	FG4D	GB
2014-03-28	(expected) grantORIGINAL CODE: 0009210GRAA	GRAA	EP
2014-03-11	Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS	GRAS	EP
2014-01-01	Intention to grant announcedINTG	INTG	EP
2013-12-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2013-12-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2013-12-18	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2013-12-02	Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP	GRAP	EP
2013-11-11	Amendment of ipc main classPREVIOUS MAIN CLASS: A61K0039020000R079	R079	DE
2013-09-11	Party data changed (applicant data changed or rights of an application transferred)RAP1	RAP1	EP
2013-03-06	Supplementary search report drawn up and despatchedA4	A4	EP
2013-03-06	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2013-03-06	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2013-03-06	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2012-08-15	Request for extension of the european patent (deleted)DAX	DAX	EP
2010-04-28	Request for examination filed17P	17P	EP
2010-04-28	Designated contracting statesAK	AK	EP
2010-04-28	Request for extension of the european patentAX	AX	EP
2010-03-26	Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI	PUAI	EP

Yersinia pestis antigens, vaccine compositions, and related methods

Abstract

Term

Priority claims7

Members13

Over the term

Events

Numbers

Titles3

Classification

Designated states1